{ "version": "2.2", "instance": { "casif-20251231x20f.htm": { "nsprefix": "casi", "nsuri": "http://www.entremed.com/20251231", "dts": { "schema": { "local": [ "casif-20251231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "calculationLink": { "local": [ "casif-20251231_cal.xml" ] }, "definitionLink": { "local": [ "casif-20251231_def.xml" ] }, "labelLink": { "local": [ "casif-20251231_lab.xml" ] }, "presentationLink": { "local": [ "casif-20251231_pre.xml" ] }, "inline": { "local": [ "casif-20251231x20f.htm" ] } }, "keyStandard": 410, "keyCustom": 152, "axisStandard": 39, "axisCustom": 0, "memberStandard": 39, "memberCustom": 54, "hidden": { "total": 28, "http://www.entremed.com/20251231": 2, "http://fasb.org/us-gaap/2025": 22, "http://xbrl.sec.gov/dei/2025": 4 }, "contextCount": 281, "entityCount": 1, "segmentCount": 101, "elementCount": 957, "unitCount": 16, "baseTaxonomies": { "http://fasb.org/us-gaap/2025": 1091, "http://xbrl.sec.gov/dei/2025": 45, "http://xbrl.sec.gov/cyd/2025": 12, "http://fasb.org/srt/2025": 5, "http://xbrl.sec.gov/ecd/2025": 1 }, "report": { "R1": { "role": "http://www.entremed.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.entremed.com/role/StatementConsolidatedBalanceSheets", "longName": "995200100 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R3": { "role": "http://www.entremed.com/role/StatementConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R5": { "role": "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "longName": "995200300 - Statement - Consolidated Statements of Stockholders' Equity", "shortName": "Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XaJKhg03U0G5iO5m8f-NGA", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XaJKhg03U0G5iO5m8f-NGA", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows", "longName": "995200400 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:Depreciation", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R7": { "role": "http://www.entremed.com/role/DisclosureDescriptionOfBusiness", "longName": "995210101 - Disclosure - DESCRIPTION OF BUSINESS", "shortName": "DESCRIPTION OF BUSINESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:BasisOfAccounting", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:BasisOfAccounting", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995210201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestments", "longName": "995210301 - Disclosure - INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS", "shortName": "INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.entremed.com/role/DisclosureInventories", "longName": "995210401 - Disclosure - INVENTORIES", "shortName": "INVENTORIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.entremed.com/role/DisclosureLeases", "longName": "995210501 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.entremed.com/role/DisclosurePropertyPlantAndEquipment", "longName": "995210601 - Disclosure - PROPERTY, PLANT AND EQUIPMENT", "shortName": "PROPERTY, PLANT AND EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.entremed.com/role/DisclosureIntangibleAssets", "longName": "995210701 - Disclosure - INTANGIBLE ASSETS", "shortName": "INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilities", "longName": "995210801 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES, AND OTHER LIABILITIES", "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES, AND OTHER LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "casi:AccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "casi:AccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.entremed.com/role/DisclosureShortTermBorrowings", "longName": "995210901 - Disclosure - SHORT TERM BORROWINGS", "shortName": "SHORT TERM BORROWINGS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.entremed.com/role/DisclosureGrants", "longName": "995211001 - Disclosure - GRANTS", "shortName": "GRANTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "casi:GrantsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "casi:GrantsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowing", "longName": "995211101 - Disclosure - REDEEMABLE NONCONTROLLING INTEREST AND A LONG TERM BORROWING", "shortName": "REDEEMABLE NONCONTROLLING INTEREST AND A LONG TERM BORROWING", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "casi:RedeemableNonControllingInterestAndLongTermBorrowingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "casi:RedeemableNonControllingInterestAndLongTermBorrowingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.entremed.com/role/DisclosureShareholdersDeficitEquity", "longName": "995211201 - Disclosure - SHAREHOLDERS' (DEFICIT) EQUITY", "shortName": "SHAREHOLDERS' (DEFICIT) EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.entremed.com/role/DisclosureNetLossPerShare", "longName": "995211301 - Disclosure - NET LOSS PER SHARE", "shortName": "NET LOSS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.entremed.com/role/DisclosureEmployeeBenefitPlan", "longName": "995211401 - Disclosure - EMPLOYEE BENEFIT PLAN", "shortName": "EMPLOYEE BENEFIT PLAN", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.entremed.com/role/DisclosureShareBasedCompensation", "longName": "995211501 - Disclosure - SHARE-BASED COMPENSATION", "shortName": "SHARE-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.entremed.com/role/DisclosureIncomeTaxes", "longName": "995211601 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.entremed.com/role/DisclosureFairValueMeasurements", "longName": "995211701 - Disclosure - FAIR VALUE MEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.entremed.com/role/DisclosureRelatedPartyTransactions", "longName": "995211801 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.entremed.com/role/DisclosureCommitmentsAndContingencies", "longName": "995211901 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.entremed.com/role/DisclosureRestrictedNetAssets", "longName": "995212001 - Disclosure - RESTRICTED NET ASSETS", "shortName": "RESTRICTED NET ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "casi:RestrictedNetAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "casi:RestrictedNetAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.entremed.com/role/DisclosureSubsequentEvents", "longName": "995212101 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrant", "longName": "995212201 - Disclosure - CONDENSED FINANCIAL INFORMATION OF REGISTRANT", "shortName": "CONDENSED FINANCIAL INFORMATION OF REGISTRANT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R29": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": null }, "R30": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R31": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsTables", "longName": "99930303 - Disclosure - INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS (Tables)", "shortName": "INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.entremed.com/role/DisclosureInventoriesTables", "longName": "99930403 - Disclosure - INVENTORIES (Tables)", "shortName": "INVENTORIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.entremed.com/role/DisclosureLeasesTables", "longName": "99930503 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "casi:DisclosureOfLeaseOnConsolidatedBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "casi:DisclosureOfLeaseOnConsolidatedBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentTables", "longName": "99930603 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)", "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.entremed.com/role/DisclosureIntangibleAssetsTables", "longName": "99930703 - Disclosure - INTANGIBLE ASSETS (Tables)", "shortName": "INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesTables", "longName": "99930803 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES, AND OTHER LIABILITIES (Tables)", "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES, AND OTHER LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "casi:ScheduleOfAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "casi:AccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "casi:ScheduleOfAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "casi:AccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingTables", "longName": "99931103 - Disclosure - REDEEMABLE NONCONTROLLING INTEREST AND A LONG TERM BORROWING (Tables)", "shortName": "REDEEMABLE NONCONTROLLING INTEREST AND A LONG TERM BORROWING (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityTables", "longName": "99931203 - Disclosure - SHAREHOLDERS' (DEFICIT) EQUITY (Tables)", "shortName": "SHAREHOLDERS' (DEFICIT) EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "casi:ScheduleOfWarrantActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "casi:ScheduleOfWarrantActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.entremed.com/role/DisclosureNetLossPerShareTables", "longName": "99931303 - Disclosure - NET LOSS PER SHARE (Tables)", "shortName": "NET LOSS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.entremed.com/role/DisclosureShareBasedCompensationTables", "longName": "99931503 - Disclosure - SHARE-BASED COMPENSATION (Tables)", "shortName": "SHARE-BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.entremed.com/role/DisclosureIncomeTaxesTables", "longName": "99931603 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.entremed.com/role/DisclosureFairValueMeasurementsTables", "longName": "99931703 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantTables", "longName": "99932203 - Disclosure - CONDENSED FINANCIAL INFORMATION OF REGISTRANT (Tables)", "shortName": "CONDENSED FINANCIAL INFORMATION OF REGISTRANT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "longName": "99940101 - Disclosure - DESCRIPTION OF BUSINESS - Liquidity and Capital Resources (Details)", "shortName": "DESCRIPTION OF BUSINESS - Liquidity and Capital Resources (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "casi:NumberOfWhollyOwnedSubsidiaries", "unitRef": "Unit_Standard_subsidiary_8OHsP6YO90uR3pDMG06E-w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:BasisOfAccounting", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "casi:CurrentAssetsNet", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R47": { "role": "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsChinaResourcesPharmaceuticalCommercialGroupInternationalTradingCoLtdDetails", "longName": "99940102 - Disclosure - DESCRIPTION OF BUSINESS - License and Distribution Agreements (China Resources Pharmaceutical Commercial Group International Trading Co., Ltd.) (Details)", "shortName": "DESCRIPTION OF BUSINESS - License and Distribution Agreements (China Resources Pharmaceutical Commercial Group International Trading Co., Ltd.) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "Duration_3_1_2019_To_3_31_2019_srt_CounterpartyNameAxis_casi_ChinaResourcesPharmaceuticalCommercialGroupInternationalTradingCoLtdMember_j2YRM7rcXkaYLKd4SM9WFw", "name": "casi:NonRoyaltyExclusiveDistributionPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_3_1_2019_To_3_31_2019_srt_CounterpartyNameAxis_casi_ChinaResourcesPharmaceuticalCommercialGroupInternationalTradingCoLtdMember_j2YRM7rcXkaYLKd4SM9WFw", "name": "casi:NonRoyaltyExclusiveDistributionPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsGuangzhouGloriaBiosciencesCoLtdDetails", "longName": "99940103 - Disclosure - DESCRIPTION OF BUSINESS - License and Distribution Agreements (Guangzhou Gloria Biosciences Co., Ltd.) (Details)", "shortName": "DESCRIPTION OF BUSINESS - License and Distribution Agreements (Guangzhou Gloria Biosciences Co., Ltd.) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_1_31_2025_srt_CounterpartyNameAxis_casi_GuangzhouGloriaBiosciencesCoLtdMember_vyFsEqwNfEyocQMHRBePTg", "name": "casi:TermOfAgreement", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_1_31_2025_srt_CounterpartyNameAxis_casi_GuangzhouGloriaBiosciencesCoLtdMember_vyFsEqwNfEyocQMHRBePTg", "name": "casi:TermOfAgreement", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPrecisionAutoimmuneTherapeuticsCoLtdDetails", "longName": "99940104 - Disclosure - DESCRIPTION OF BUSINESS - License and Distribution Agreements (Precision Autoimmune Therapeutics Co., Ltd) (Details)", "shortName": "DESCRIPTION OF BUSINESS - License and Distribution Agreements (Precision Autoimmune Therapeutics Co., Ltd) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "Duration_5_1_2022_To_5_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_casi_PrecisionAutoimmuneTherapeuticsCoLtdMember_phx9a11HOEm52TfysiIrrQ", "name": "casi:UpfrontPayment", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": null }, "R50": { "role": "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsJuventasCellTherapyLtdDetails", "longName": "99940105 - Disclosure - DESCRIPTION OF BUSINESS - License and Distribution Agreements (Juventas Cell Therapy Ltd.) (Details)", "shortName": "DESCRIPTION OF BUSINESS - License and Distribution Agreements (Juventas Cell Therapy Ltd.) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "As_Of_3_2_2024_UDAOM_TCL0WoBc228k76mw", "name": "casi:MaximumValueOfEntityAssetsFreezed", "unitRef": "Unit_Standard_CNY_Al0e8bC86UO_Ou6OwwLP6w", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_2_2024_UDAOM_TCL0WoBc228k76mw", "name": "casi:MaximumValueOfEntityAssetsFreezed", "unitRef": "Unit_Standard_CNY_Al0e8bC86UO_Ou6OwwLP6w", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails", "longName": "99940106 - Disclosure - DESCRIPTION OF BUSINESS - License and Distribution Agreements (BioInvent International AB) (Details)", "shortName": "DESCRIPTION OF BUSINESS - License and Distribution Agreements (BioInvent International AB) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_casi_BioinventInternationalAbMember_ehaFsxozu0K3g5o9AOzPWg", "name": "casi:UpfrontPayment", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R52": { "role": "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBlackBeltTherapeuticsLimitedDetails", "longName": "99940107 - Disclosure - DESCRIPTION OF BUSINESS - License and Distribution Agreements (Black Belt Therapeutics Limited) (Details)", "shortName": "DESCRIPTION OF BUSINESS - License and Distribution Agreements (Black Belt Therapeutics Limited) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "Duration_4_1_2019_To_4_30_2019_srt_CounterpartyNameAxis_casi_BlackBeltTherapeuticsLimitedMember_hRqO9nuoPEi8FsKY6AhWUw", "name": "casi:UpfrontPayment", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2019_To_4_30_2019_srt_CounterpartyNameAxis_casi_BlackBeltTherapeuticsLimitedMember_hRqO9nuoPEi8FsKY6AhWUw", "name": "casi:UpfrontPayment", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsCleaveTherapeuticsIncDetails", "longName": "99940108 - Disclosure - DESCRIPTION OF BUSINESS - License and Distribution Agreements (Cleave Therapeutics, Inc.) (Details)", "shortName": "DESCRIPTION OF BUSINESS - License and Distribution Agreements (Cleave Therapeutics, Inc.) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_7_18_2023_To_7_18_2023_us-gaap_TypeOfArrangementAxis_casi_AssignmentAgreementWithCleaveMember_SGyXL4YQx0il8d__SBsckQ", "name": "us-gaap:ExtinguishmentOfDebtAmount", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_18_2023_To_7_18_2023_us-gaap_TypeOfArrangementAxis_casi_AssignmentAgreementWithCleaveMember_SGyXL4YQx0il8d__SBsckQ", "name": "us-gaap:ExtinguishmentOfDebtAmount", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPharmathenGlobalBvDetails", "longName": "99940109 - Disclosure - DESCRIPTION OF BUSINESS - License and Distribution Agreements (Pharmathen Global BV) (Details)", "shortName": "DESCRIPTION OF BUSINESS - License and Distribution Agreements (Pharmathen Global BV) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_casi_PharmathenGlobalBvMember_pLtlJdbCqUCwcYOMQZuU9w", "name": "casi:UpfrontPayment", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_casi_PharmathenGlobalBvMember_pLtlJdbCqUCwcYOMQZuU9w", "name": "casi:UpfrontPayment", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentReportingDetails", "longName": "99940201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Unit_Standard_segment_IlyFDyWGE0eccZS-bgDgng", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Unit_Standard_segment_IlyFDyWGE0eccZS-bgDgng", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsRisksDetails", "longName": "99940202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentrations Risks (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentrations Risks (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "casi:NumberOfMajorSuppliers", "unitRef": "Unit_Standard_item_iIHdMRMK_UK2hKtCRKbd7g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "casi:NumberOfMajorSuppliers", "unitRef": "Unit_Standard_item_iIHdMRMK_UK2hKtCRKbd7g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails", "longName": "99940203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_srt_StatementGeographicalAxis_country_CN_jUGEFxhvmUKP_REWTuv0_g", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R58": { "role": "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPrepaidExpensesAndOtherDetails", "longName": "99940204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Prepaid expenses and other (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Prepaid expenses and other (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:ValueAddedTaxReceivable", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:ValueAddedTaxReceivable", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPpeDetails", "longName": "99940205 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - PPE (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - PPE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "As_Of_12_31_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_casi_FurnitureAndEquipmentMember_hCohhRKJC0agRNMlIeQX8w", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_casi_FurnitureAndEquipmentMember_hCohhRKJC0agRNMlIeQX8w", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails", "longName": "99940301 - Disclosure - INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - Investment in equity securities, at fair value-BioInvent International AB ordinary shares and warrants (Details)", "shortName": "INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - Investment in equity securities, at fair value-BioInvent International AB ordinary shares and warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "As_Of_10_31_2020_srt_CounterpartyNameAxis_casi_BioinventInternationalAbMember_IoQrIgUvO0CCm-wyg6bxzw", "name": "casi:EquityMethodInvestmentInvestmentToBeMade", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_10_31_2020_srt_CounterpartyNameAxis_casi_BioinventInternationalAbMember_IoQrIgUvO0CCm-wyg6bxzw", "name": "casi:EquityMethodInvestmentInvestmentToBeMade", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsBioinventInternationalAbSummaryOfInvestmentsDetails", "longName": "99940302 - Disclosure - INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - BioInvent International AB - Summary of Investments (Details)", "shortName": "INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - BioInvent International AB - Summary of Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "As_Of_12_31_2024_Jv68SmJFdkic7vGFWpNx0w", "name": "us-gaap:InvestmentOwnedAtCost", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_Jv68SmJFdkic7vGFWpNx0w", "name": "us-gaap:InvestmentOwnedAtCost", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsSummaryOfLongTermInvestmentsDetails", "longName": "99940303 - Disclosure - INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - Summary of Long-term investments (Details)", "shortName": "INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - Summary of Long-term investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:DebtSecuritiesTradingAndEquitySecuritiesFvNiCost", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "casi:ScheduleOfLongTermInvestmentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_Jv68SmJFdkic7vGFWpNx0w", "name": "us-gaap:DebtSecuritiesTradingAndEquitySecuritiesFvNiCost", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "us-gaap:DebtSecuritiesTradingAndEquitySecuritiesFvNiCost", "p", "td", "tr", "table", "casi:ScheduleOfLongTermInvestmentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R63": { "role": "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails", "longName": "99940304 - Disclosure - INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - Investment in equity securities, at fair value-Alesta Therapeutics B.V. (Details)", "shortName": "INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - Investment in equity securities, at fair value-Alesta Therapeutics B.V. (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:PaymentsToAcquireEquityMethodInvestments", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2019_To_4_30_2019_srt_CounterpartyNameAxis_casi_BlackBeltTxLimitedMember_JIva38luB06l1BPFPC105g", "name": "us-gaap:PaymentsToAcquireEquityMethodInvestments", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R64": { "role": "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueCleaveTherapeuticsIncDetails", "longName": "99940305 - Disclosure - INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - Investment in equity securities, at fair value-Cleave Therapeutics, Inc. (Details)", "shortName": "INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - Investment in equity securities, at fair value-Cleave Therapeutics, Inc. (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_4EHT0j9hLk2o_XkXVoTvaA", "name": "us-gaap:DebtSecuritiesRealizedGainLoss", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2021_srt_CounterpartyNameAxis_casi_CleaveTherapeuticsIncMember_yOk__whNU0eepp4Qd1gjWg", "name": "casi:InvestmentInConvertibleNote", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R65": { "role": "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails", "longName": "99940306 - Disclosure - INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - Investment in Precision Autoimmune Therapeutics Co Ltd (PAT) (Details)", "shortName": "INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - Investment in Precision Autoimmune Therapeutics Co Ltd (PAT) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_casi_PrecisionAutoimmuneTherapeuticsCoLtdMember_WFAVb3mtKEeEsvFHmablcQ", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R66": { "role": "http://www.entremed.com/role/DisclosureInventoriesDetails", "longName": "99940401 - Disclosure - INVENTORIES (Details)", "shortName": "INVENTORIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:InventoryNet", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": null }, "R67": { "role": "http://www.entremed.com/role/DisclosureInventoriesScheduleOfInventoryDetails", "longName": "99940402 - Disclosure - INVENTORIES - Schedule of Inventory (Details)", "shortName": "INVENTORIES - Schedule of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.entremed.com/role/DisclosureLeasesDetails", "longName": "99940501 - Disclosure - LEASES - (Details)", "shortName": "LEASES - (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "casi:NumberOfOperatingLeases", "unitRef": "Unit_Standard_lease_x8QOlpr43EiddwsGxpoLaw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "casi:NumberOfOperatingLeases", "unitRef": "Unit_Standard_lease_x8QOlpr43EiddwsGxpoLaw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.entremed.com/role/DisclosureLeasesRightOfUseAssetsAndLiabilitiesDetails", "longName": "99940502 - Disclosure - LEASES - Right of Use Assets and Liabilities (Details)", "shortName": "LEASES - Right of Use Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": null }, "R70": { "role": "http://www.entremed.com/role/DisclosureLeasesSupplementalCashFlowDetails", "longName": "99940503 - Disclosure - LEASES - Supplemental Cash Flow (Details)", "shortName": "LEASES - Supplemental Cash Flow (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "casi:DisclosureOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "casi:DisclosureOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.entremed.com/role/DisclosureLeasesFutureUndiscountedCashFlowsDetails", "longName": "99940504 - Disclosure - LEASES - Future Undiscounted Cash Flows (Details)", "shortName": "LEASES - Future Undiscounted Cash Flows (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentNarrativesDetails", "longName": "99940601 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narratives (Details)", "shortName": "PROPERTY, PLANT AND EQUIPMENT - Narratives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentByTypeDetails", "longName": "99940602 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - By type (Details)", "shortName": "PROPERTY, PLANT AND EQUIPMENT - By type (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:LeaseholdImprovementsGross", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:LeaseholdImprovementsGross", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.entremed.com/role/DisclosureIntangibleAssetsNarrativesDetails", "longName": "99940701 - Disclosure - INTANGIBLE ASSETS - Narratives (Details)", "shortName": "INTANGIBLE ASSETS - Narratives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_H6S0YfA9LEG0brZ9I-eRaQ", "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_7_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_casi_FolotynMember_757mRq-xGEuu4kR-w1bUtQ", "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R75": { "role": "http://www.entremed.com/role/DisclosureIntangibleAssetsNetDefiniteLivedIntangibleAssetsDetails", "longName": "99940702 - Disclosure - INTANGIBLE ASSETS - Net Definite-lived Intangible Assets (Details)", "shortName": "INTANGIBLE ASSETS - Net Definite-lived Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R76": { "role": "http://www.entremed.com/role/DisclosureIntangibleAssetsIntangibleAssetsRollforwardDetails", "longName": "99940703 - Disclosure - INTANGIBLE ASSETS - Intangible Assets Rollforward (Details)", "shortName": "INTANGIBLE ASSETS - Intangible Assets Rollforward (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "As_Of_12_31_2024_Jv68SmJFdkic7vGFWpNx0w", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_H6S0YfA9LEG0brZ9I-eRaQ", "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R77": { "role": "http://www.entremed.com/role/DisclosureIntangibleAssetsExpectedFutureAmortizationExpenseDetails", "longName": "99940704 - Disclosure - INTANGIBLE ASSETS - Expected Future Amortization Expense (Details)", "shortName": "INTANGIBLE ASSETS - Expected Future Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails", "longName": "99940801 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES, AND OTHER LIABILITIES (Details)", "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES, AND OTHER LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:OtherEmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "casi:ScheduleOfAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesTableTextBlock", "casi:AccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:OtherEmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "casi:ScheduleOfAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesTableTextBlock", "casi:AccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.entremed.com/role/DisclosureShortTermBorrowingsDetails", "longName": "99940901 - Disclosure - SHORT TERM BORROWINGS (Details)", "shortName": "SHORT TERM BORROWINGS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "As_Of_9_30_2025_dei_LegalEntityAxis_casi_CasiChinaMember_us-gaap_LineOfCreditFacilityAxis_casi_BankOfNanjingMember_11gaggzFN0C3S0dPH5_7gw", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "Unit_Standard_CNY_Al0e8bC86UO_Ou6OwwLP6w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:ShortTermDebtTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2025_dei_LegalEntityAxis_casi_CasiChinaMember_us-gaap_LineOfCreditFacilityAxis_casi_BankOfNanjingMember_11gaggzFN0C3S0dPH5_7gw", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "Unit_Standard_CNY_Al0e8bC86UO_Ou6OwwLP6w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:ShortTermDebtTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.entremed.com/role/DisclosureGrantsDetails", "longName": "99941001 - Disclosure - GRANTS (Details)", "shortName": "GRANTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_H6S0YfA9LEG0brZ9I-eRaQ", "name": "us-gaap:OtherIncome", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_H6S0YfA9LEG0brZ9I-eRaQ", "name": "us-gaap:OtherIncome", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails", "longName": "99941101 - Disclosure - REDEEMABLE NONCONTROLLING INTEREST AND A LONG TERM BORROWING (Details)", "shortName": "REDEEMABLE NONCONTROLLING INTEREST AND A LONG TERM BORROWING (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "As_Of_12_31_2023_K4l6taIJM0m5CLbZcAvDoQ", "name": "casi:InvestmentReturnPayableInInstallments", "unitRef": "Unit_Standard_CNY_Al0e8bC86UO_Ou6OwwLP6w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "casi:RedeemableNonControllingInterestAndLongTermBorrowingTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_K4l6taIJM0m5CLbZcAvDoQ", "name": "casi:InvestmentReturnPayableInInstallments", "unitRef": "Unit_Standard_CNY_Al0e8bC86UO_Ou6OwwLP6w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "casi:RedeemableNonControllingInterestAndLongTermBorrowingTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingChangesInRedeemableNoncontrollingInterestDetails", "longName": "99941102 - Disclosure - REDEEMABLE NONCONTROLLING INTEREST AND A LONG TERM BORROWING - Changes in Redeemable Noncontrolling Interest (Details)", "shortName": "REDEEMABLE NONCONTROLLING INTEREST AND A LONG TERM BORROWING - Changes in Redeemable Noncontrolling Interest (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "As_Of_12_31_2022_k5FnysZLSU2OA8HGRNqtMw", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCommonCarryingAmount", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_k5FnysZLSU2OA8HGRNqtMw", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCommonCarryingAmount", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails", "longName": "99941201 - Disclosure - SHAREHOLDERS' (DEFICIT) EQUITY (Details)", "shortName": "SHAREHOLDERS' (DEFICIT) EQUITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Unit_Standard_shares_vM8iurYkBEitHVRGsjSyvw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2023_d_qMHT5SQkGKM5Drh99wGw", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Unit_Standard_shares_vM8iurYkBEitHVRGsjSyvw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R84": { "role": "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityWarrantsActivityDetails", "longName": "99941202 - Disclosure - SHAREHOLDERS' (DEFICIT) EQUITY - Warrants Activity (Details)", "shortName": "SHAREHOLDERS' (DEFICIT) EQUITY - Warrants Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "As_Of_12_31_2024_Jv68SmJFdkic7vGFWpNx0w", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_vM8iurYkBEitHVRGsjSyvw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "casi:ScheduleOfWarrantActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_H6S0YfA9LEG0brZ9I-eRaQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Unit_Standard_shares_vM8iurYkBEitHVRGsjSyvw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "casi:ScheduleOfWarrantActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R85": { "role": "http://www.entremed.com/role/DisclosureNetLossPerShareDetails", "longName": "99941301 - Disclosure - NET LOSS PER SHARE (Details)", "shortName": "NET LOSS PER SHARE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_casi_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_casi_July2024PrivateInvestmentInPublicEquityFinancingMember_jeDuG-f7VUOssZryNtdBUA", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_vM8iurYkBEitHVRGsjSyvw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_casi_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_casi_July2024PrivateInvestmentInPublicEquityFinancingMember_jeDuG-f7VUOssZryNtdBUA", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_vM8iurYkBEitHVRGsjSyvw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R86": { "role": "http://www.entremed.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareComputationDetails", "longName": "99941302 - Disclosure - NET LOSS PER SHARE - Basic and diluted net loss per share computation (Details)", "shortName": "NET LOSS PER SHARE - Basic and diluted net loss per share computation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": null }, "R87": { "role": "http://www.entremed.com/role/DisclosureEmployeeBenefitPlanDetails", "longName": "99941401 - Disclosure - EMPLOYEE BENEFIT PLAN (Details)", "shortName": "EMPLOYEE BENEFIT PLAN (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R88": { "role": "http://www.entremed.com/role/DisclosureShareBasedCompensationCompensationExpenseDetails", "longName": "99941501 - Disclosure - SHARE-BASED COMPENSATION - Compensation Expense (Details)", "shortName": "SHARE-BASED COMPENSATION - Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:ShareBasedCompensation", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Wq8gDFcgN0G854VyYRqiiA", "name": "us-gaap:ShareBasedCompensation", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R89": { "role": "http://www.entremed.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsDetails", "longName": "99941502 - Disclosure - SHARE-BASED COMPENSATION - Weighted-Average Assumptions (Details)", "shortName": "SHARE-BASED COMPENSATION - Weighted-Average Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "Duration_7_8_2024_To_7_8_2024_fZZLzHp0X0yZT7wAf5kbdg", "name": "casi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPlanModificationInPeriodWeightedAverageModificationDateFairValue", "unitRef": "Unit_Divide_USD_shares_MvjzPlFNTEWI2VoDQ5iIvQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_8_2024_To_7_8_2024_fZZLzHp0X0yZT7wAf5kbdg", "name": "casi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPlanModificationInPeriodWeightedAverageModificationDateFairValue", "unitRef": "Unit_Divide_USD_shares_MvjzPlFNTEWI2VoDQ5iIvQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails", "longName": "99941503 - Disclosure - SHARE-BASED COMPENSATION - Options Outstanding (Details)", "shortName": "SHARE-BASED COMPENSATION - Options Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_C3dhh9FZAUOFE9LFKbU0MA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_vM8iurYkBEitHVRGsjSyvw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaap_EmployeeStockOptionMember_izJ5tGfptEOM8l7pJyJOrQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_vM8iurYkBEitHVRGsjSyvw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R91": { "role": "http://www.entremed.com/role/DisclosureShareBasedCompensationStockOptionOutstandingDetails", "longName": "99941504 - Disclosure - SHARE-BASED COMPENSATION - Stock Option Outstanding (Details)", "shortName": "SHARE-BASED COMPENSATION - Stock Option Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "unitRef": "Unit_Standard_shares_vM8iurYkBEitHVRGsjSyvw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "unitRef": "Unit_Standard_shares_vM8iurYkBEitHVRGsjSyvw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R92": { "role": "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails", "longName": "99941505 - Disclosure - SHARE-BASED COMPENSATION (Details)", "shortName": "SHARE-BASED COMPENSATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "Duration_7_12_2024_To_7_12_2024_R_hxvklW6Ey1aIYd35L8wQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_12_2024_To_7_12_2024_R_hxvklW6Ey1aIYd35L8wQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R93": { "role": "http://www.entremed.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesDetails", "longName": "99941601 - Disclosure - INCOME TAXES - Loss Before Income Taxes (Details)", "shortName": "INCOME TAXES - Loss Before Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R94": { "role": "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails", "longName": "99941602 - Disclosure - INCOME TAXES - Deferred Income Tax Assets And Liabilities (Details)", "shortName": "INCOME TAXES - Deferred Income Tax Assets And Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R95": { "role": "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails", "longName": "99941603 - Disclosure - INCOME TAXES - Reconciliation of income tax (Details)", "shortName": "INCOME TAXES - Reconciliation of income tax (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R96": { "role": "http://www.entremed.com/role/DisclosureIncomeTaxesValuationAllowanceDetails", "longName": "99941604 - Disclosure - INCOME TAXES - Valuation allowance (Details)", "shortName": "INCOME TAXES - Valuation allowance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "As_Of_12_31_2024_Jv68SmJFdkic7vGFWpNx0w", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "casi:IncreaseDecreaseInDeferredTaxAssets", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R97": { "role": "http://www.entremed.com/role/DisclosureIncomeTaxesGrossUnrecognizedTaxBenefitsDetails", "longName": "99941605 - Disclosure - INCOME TAXES - Gross Unrecognized Tax Benefits (Details)", "shortName": "INCOME TAXES - Gross Unrecognized Tax Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "As_Of_12_31_2024_Jv68SmJFdkic7vGFWpNx0w", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": null }, "R98": { "role": "http://www.entremed.com/role/DisclosureIncomeTaxesDetails", "longName": "99941606 - Disclosure - INCOME TAXES (Details)", "shortName": "INCOME TAXES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R99": { "role": "http://www.entremed.com/role/DisclosureFairValueMeasurementsFinancialAndNonFinancialAssetsAndLiabilitiesDetails", "longName": "99941701 - Disclosure - FAIR VALUE MEASUREMENTS - Financial and Non-Financial Assets and Liabilities (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Financial and Non-Financial Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hMj5wqwZbEOtuN0fiWI6cw", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_VK0DoFoxjkqnk1xgYm-2SQ", "name": "casi:InvestmentsFairValueDisclosureEquitySecuritiesInOrdinaryShares", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R100": { "role": "http://www.entremed.com/role/DisclosureFairValueMeasurementsQuantitativeInformationAboutLevel3FairValueMeasurementsDetails", "longName": "99941702 - Disclosure - FAIR VALUE MEASUREMENTS - Quantitative Information about Level 3 Fair Value Measurements (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Quantitative Information about Level 3 Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hMj5wqwZbEOtuN0fiWI6cw", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_f3QOV42YqUSdzM2zqT0YQg", "name": "us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput", "unitRef": "Unit_Standard_pure_PqzaoNxitkaQ4a8LSRm6hQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R101": { "role": "http://www.entremed.com/role/DisclosureFairValueMeasurementsDetails", "longName": "99941703 - Disclosure - FAIR VALUE MEASUREMENTS (Details)", "shortName": "FAIR VALUE MEASUREMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_casi_FolotynMember_wBkl6XKQr0m1kWHuPlGBgw", "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_casi_FolotynMember_wBkl6XKQr0m1kWHuPlGBgw", "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R102": { "role": "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails", "longName": "99941801 - Disclosure - RELATED PARTY TRANSACTIONS - Convertible Note Financing (Details)", "shortName": "RELATED PARTY TRANSACTIONS - Convertible Note Financing (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_MvjzPlFNTEWI2VoDQ5iIvQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_casi_EtpGlobalIiiFundLpMember_us-gaap_DebtInstrumentAxis_casi_ConvertibleNotesTrancheOneMember_V71JOMxefEqfua6d-bZbLQ", "name": "casi:AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertibleNotes", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R103": { "role": "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsPurchaseOfOrdinarySharesDetails", "longName": "99941802 - Disclosure - RELATED PARTY TRANSACTIONS - Purchase of Ordinary Shares (Details)", "shortName": "RELATED PARTY TRANSACTIONS - Purchase of Ordinary Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "Duration_9_1_2025_To_9_30_2025_srt_CounterpartyNameAxis_casi_HuiyingMemorialFoundationMember_us-gaap_SubsidiarySaleOfStockAxis_casi_AtMarketOffering2024Member_nyD-z1RHlE2jnXDA5jNKcw", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_vM8iurYkBEitHVRGsjSyvw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_9_1_2025_To_9_30_2025_srt_CounterpartyNameAxis_casi_HuiyingMemorialFoundationMember_us-gaap_SubsidiarySaleOfStockAxis_casi_AtMarketOffering2024Member_nyD-z1RHlE2jnXDA5jNKcw", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_vM8iurYkBEitHVRGsjSyvw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R104": { "role": "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails", "longName": "99941803 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_7_31_2024_srt_CounterpartyNameAxis_casi_HeFamilyGratMember_us-gaap_RelatedPartyTransactionAxis_us-gaap_RelatedPartyMember_n2kr0ae0IEmwsJHiAuv4Tg", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_vM8iurYkBEitHVRGsjSyvw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_7_31_2024_srt_CounterpartyNameAxis_casi_HeFamilyGratMember_us-gaap_RelatedPartyTransactionAxis_us-gaap_RelatedPartyMember_n2kr0ae0IEmwsJHiAuv4Tg", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_vM8iurYkBEitHVRGsjSyvw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R105": { "role": "http://www.entremed.com/role/DisclosureCommitmentsAndContingenciesDetails", "longName": "99941901 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_casi_CleaveTherapeuticsIncMember_f0M0A8wdgEa9bzmdItu9wg", "name": "casi:NumberMilestonesAchieved", "unitRef": "Unit_Standard_Milestone_oxEu9PfG9USeYWTz3CR9nQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_srt_CounterpartyNameAxis_casi_CleaveTherapeuticsIncMember_f0M0A8wdgEa9bzmdItu9wg", "name": "casi:NumberMilestonesAchieved", "unitRef": "Unit_Standard_Milestone_oxEu9PfG9USeYWTz3CR9nQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R106": { "role": "http://www.entremed.com/role/DisclosureRestrictedNetAssetsDetails", "longName": "99942001 - Disclosure - RESTRICTED NET ASSETS (Details)", "shortName": "RESTRICTED NET ASSETS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:RestrictedInvestments", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "casi:RestrictedNetAssetsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:RestrictedInvestments", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "casi:RestrictedNetAssetsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true, "unique": true } }, "R107": { "role": "http://www.entremed.com/role/DisclosureSubsequentEventsDetails", "longName": "99942101 - Disclosure - SUBSEQUENT EVENTS (Details)", "shortName": "SUBSEQUENT EVENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_MvjzPlFNTEWI2VoDQ5iIvQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": null }, "R108": { "role": "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "longName": "99942201 - Disclosure - CONDENSED FINANCIAL INFORMATION OF REGISTRANT - Condensed Balance Sheets (Details)", "shortName": "CONDENSED FINANCIAL INFORMATION OF REGISTRANT - Condensed Balance Sheets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "As_Of_12_31_2025_pL9Ai59L30CizTM9KKd3oA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_O7gQzxHXEE-j6GGcsVbB_w", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R109": { "role": "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails", "longName": "99942202 - Disclosure - CONDENSED FINANCIAL INFORMATION OF REGISTRANT - Condensed Statements of Operations and Comprehensive Loss (Details)", "shortName": "CONDENSED FINANCIAL INFORMATION OF REGISTRANT - Condensed Statements of Operations and Comprehensive Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_pqsUPOe40UiOf93J2YBc-g", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "srt:ScheduleOfCondensedIncomeStatementTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } }, "R110": { "role": "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "longName": "99942203 - Disclosure - CONDENSED FINANCIAL INFORMATION OF REGISTRANT - Condensed Statements of Cash Flows (Details)", "shortName": "CONDENSED FINANCIAL INFORMATION OF REGISTRANT - Condensed Statements of Cash Flows (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_fPrdloln_0m14OepAtj3Wg", "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_12_31_2025_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_pqsUPOe40UiOf93J2YBc-g", "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "unitRef": "Unit_Standard_USD_HYyLmcTyWE-Nr2VNRxPXGg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "casif-20251231x20f.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails", "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued And Other Liabilities, Current", "totalLabel": "Accrued and other current liabilities", "verboseLabel": "Accrued and other current liabilities", "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r62", "r1199" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsReceivableMember", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsRisksDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "terseLabel": "Accounts receivable", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r1075", "r1399" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net", "verboseLabel": "Accounts receivable, net of nil expected credit loss", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1409" ] }, "casi_AccretionOfRedeemableNonControllingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "AccretionOfRedeemableNonControllingInterest", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingChangesInRedeemableNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of Accretion of Redeemable Non Controlling Interest.", "label": "Accretion of Redeemable Non Controlling Interest", "verboseLabel": "Accretion of redeemable noncontrolling interest" } } }, "auth_ref": [] }, "casi_AccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "AccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilities" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accrued and other current liabilities and other liabilities.", "label": "Accrued and Other Current Liabilities and Other Liabilities Disclosure [Text Block]", "terseLabel": "ACCRUED AND OTHER CURRENT LIABILITIES, AND OTHER LIABILITIES" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Payable to professional service", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r65" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentByTypeDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentByTypeDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r38", "r189", "r850" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r22", "r23", "r83", "r198", "r844", "r878", "r879", "r1510" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "verboseLabel": "Accumulated Other Comprehensive Income (Loss)", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r3", "r15", "r23", "r661", "r664", "r741", "r874", "r875", "r1372", "r1373", "r1374", "r1391", "r1392", "r1393", "r1394" ] }, "casi_AcrotechBiopharmaL.l.c.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "AcrotechBiopharmaL.l.c.Member", "presentation": [ "http://www.entremed.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Acrotech Biopharma L.L.C.", "label": "Acrotech Biopharma L.L.C. [Member]", "terseLabel": "Acrotech Biopharma LLC" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r1275" ] }, "casi_AdditionalMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "AdditionalMilestonePayments", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPharmathenGlobalBvDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of additional milestone payments.", "label": "Additional Milestone Payments", "terseLabel": "Additional milestone payments" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "verboseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r75", "r1199", "r1583" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r900", "r1391", "r1392", "r1393", "r1394", "r1511", "r1585" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AddressTypeDomain", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r1288" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r1288" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r1288" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r1288" ] }, "casi_AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertibleNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertibleNotes", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from issuance of convertible notes.", "label": "Adjustments to Additional Paid in Capital, Issuance Of Convertible Notes", "terseLabel": "Deemed contribution from shareholder as a result of issuance of Convertible notes (Note 18)", "verboseLabel": "Deemed contribution from shareholder as a result of issuance of Convertible notes" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "verboseLabel": "Share-based compensation expense, net of forfeitures", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r496" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "negatedLabel": "Share issuance costs of a PIPE or ATM Transaction (Note 12)", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": [ "r16", "r116" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "casi_AggregateConsiderationForEquityInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "AggregateConsiderationForEquityInvestment", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPrecisionAutoimmuneTherapeuticsCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of aggregate consideration for equity investment.", "label": "Aggregate Consideration For Equity Investment", "terseLabel": "Aggregate consideration for equity investment", "verboseLabel": "Equity investment amount" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r1333" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1246", "r1257", "r1267", "r1300" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r1249", "r1260", "r1270", "r1303" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r1334" ] }, "casi_AgreementOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "AgreementOneMember", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to agreement one.", "label": "Agreement One [Member]", "terseLabel": "Agreement one" } } }, "auth_ref": [] }, "casi_AgreementTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "AgreementTwoMember", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to agreement two.", "label": "Agreement Two [Member]", "terseLabel": "Agreement Two" } } }, "auth_ref": [] }, "casi_AlestaTxMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "AlestaTxMember", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsSummaryOfLongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Alesta Tx.", "label": "Alesta Tx [Member]", "terseLabel": "Alesta Tx" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r1288" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r1295" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r1250", "r1261", "r1271", "r1295", "r1304", "r1308", "r1316" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r1314" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r528", "r534", "r543" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss, Current", "verboseLabel": "Accounts receivable, expected credit loss", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r199", "r309", "r353" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsIntangibleAssetsRollforwardDetails" ], "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "negatedLabel": "Amortization expense", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets." } } }, "auth_ref": [ "r11", "r223", "r383", "r391", "r1094", "r1104", "r1105", "r1107", "r1109" ] }, "casi_AmortizationOfIntangibleAssetsAndHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "AmortizationOfIntangibleAssetsAndHeldForSale", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets and assets held for sale.", "label": "Amortization Of Intangible Assets And Held For Sale", "terseLabel": "Amortization of intangible assets" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share amount (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r270" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r270" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r270" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r270" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsChinaResourcesPharmaceuticalCommercialGroupInternationalTradingCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsCleaveTherapeuticsIncDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails" ], "lang": { "en-us": { "role": { "label": "Arrangements and Non-arrangement Transactions [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r646" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r126", "r138", "r192", "r233", "r235", "r236", "r275", "r285", "r301", "r302", "r347", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r648", "r653", "r702", "r831", "r832", "r840", "r942", "r1121", "r1122", "r1132", "r1199", "r1213", "r1214", "r1225", "r1444", "r1445", "r1535" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsAbstract", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r183", "r202", "r233", "r235", "r236", "r347", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r648", "r653", "r702", "r1199", "r1444", "r1445", "r1535" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsFairValueAdjustment", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueCleaveTherapeuticsIncDetails" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Adjustment", "terseLabel": "Change in fair value of investment in equity securities", "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties." } } }, "auth_ref": [] }, "casi_AssignmentAgreementCommercialAndSalesMilestonePaymentsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "AssignmentAgreementCommercialAndSalesMilestonePaymentsPayable", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsCleaveTherapeuticsIncDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of commercial and sales milestone payments payable under the assignment agreement.", "label": "Assignment Agreement, Commercial and Sales Milestone Payments Payable", "terseLabel": "Assignment agreement, commercial and sales milestone payments payable" } } }, "auth_ref": [] }, "casi_AssignmentAgreementPercentageOfRoyaltyOnNetSalesPayable": { "xbrltype": "percentItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "AssignmentAgreementPercentageOfRoyaltyOnNetSalesPayable", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsCleaveTherapeuticsIncDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of royalty on net sales payable under the assignment agreement.", "label": "Assignment Agreement, Percentage of Royalty on Net Sales Payable", "terseLabel": "Assignment agreement, percentage of royalty on net sales payable" } } }, "auth_ref": [] }, "casi_AssignmentAgreementWithCleaveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "AssignmentAgreementWithCleaveMember", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsCleaveTherapeuticsIncDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Assignment Agreement with Cleave.", "label": "Assignment Agreement with Cleave [Member]", "terseLabel": "Assignment Agreement with Cleave" } } }, "auth_ref": [] }, "casi_AtMarketOffering2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "AtMarketOffering2024Member", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsPurchaseOfOrdinarySharesDetails", "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2024 At-the-Market offering.", "label": "At The Market Offering 2024 [Member]", "terseLabel": "Market offering 2024" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorFirmId", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r1229", "r1230", "r1253" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorLocation", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r1229", "r1230", "r1253" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorName", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r1229", "r1230", "r1253" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsFinancialAndNonFinancialAssetsAndLiabilitiesDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsQuantitativeInformationAboutLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale", "verboseLabel": "Convertible note", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r313", "r368", "r676", "r695", "r696", "r697", "r698", "r826", "r1092", "r1186", "r1189", "r1196", "r1413", "r1515", "r1516", "r1517" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Noncurrent", "terseLabel": "Available-for-sale debt securities", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r187", "r310", "r368" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r1311" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r1312" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r1307" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r1307" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r1307" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r1307" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r1307" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r1307" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AwardTypeAxis", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails", "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r499", "r500", "r501", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r523", "r524", "r525", "r526", "r527" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r1310" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1309" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r1308" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r1308" ] }, "casi_BankOfCommunicationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "BankOfCommunicationsMember", "presentation": [ "http://www.entremed.com/role/DisclosureShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to bank of communications.", "label": "Bank of Communications [Member]", "terseLabel": "Bank of Communications" } } }, "auth_ref": [] }, "casi_BankOfNanjingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "BankOfNanjingMember", "presentation": [ "http://www.entremed.com/role/DisclosureShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Bank of Nanjing.", "label": "Bank of Nanjing [Member]", "terseLabel": "Bank of Nanjing" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccounting": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BasisOfAccounting", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusiness" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting [Text Block]", "terseLabel": "DESCRIPTION OF BUSINESS", "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r1381" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r1381" ] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r1380" ] }, "casi_BioinventInternationalAbMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "BioinventInternationalAbMember", "presentation": [ "http://www.entremed.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsBioinventInternationalAbSummaryOfInvestmentsDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to BioInvent International AB.", "label": "Bioinvent International Ab [Member]", "terseLabel": "BioInvent International AB" } } }, "auth_ref": [] }, "casi_BlackBeltTherapeuticsLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "BlackBeltTherapeuticsLimitedMember", "presentation": [ "http://www.entremed.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBlackBeltTherapeuticsLimitedDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to Black Belt Therapeutics Limited (\"Black Belt\").", "label": "Black Belt Therapeutics Limited [Member]", "terseLabel": "Black Belt Therapeutics Ltd" } } }, "auth_ref": [] }, "casi_BlackBeltTxLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "BlackBeltTxLimitedMember", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Information related to Black Belt Therapeutics Limited.", "label": "Black Belt Tx Limited [Member]", "terseLabel": "Black Belt Tx Limited" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r380", "r384", "r385", "r386", "r387", "r389", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r882", "r1143", "r1144", "r1502", "r1504", "r1505" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r380", "r384", "r385", "r386", "r387", "r389", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r882", "r1143", "r1144", "r1502", "r1504", "r1505" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "BusinessContactMember", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r1230", "r1253" ] }, "casi_CASIWuxiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "CASIWuxiMember", "presentation": [ "http://www.entremed.com/role/DisclosureGrantsDetails", "http://www.entremed.com/role/DisclosureLeasesDetails", "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to CASI Wuxi.", "label": "CASI Wuxi [Member]", "terseLabel": "CASI Wuxi" } } }, "auth_ref": [] }, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "CN", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails", "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails", "http://www.entremed.com/role/DisclosureLeasesDetails", "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "CHINA", "verboseLabel": "China" } } }, "auth_ref": [] }, "us-gaap_CallOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CallOptionMember", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "label": "Call Option [Member]", "terseLabel": "Call option", "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option." } } }, "auth_ref": [ "r1035", "r1036" ] }, "casi_CallOptionToPurchaseInvestmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "CallOptionToPurchaseInvestmentPeriod", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "documentation": "Call option purchase investment period.", "label": "Call Option To Purchase Investment Period", "terseLabel": "Call option purchase investment period" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Payables related to property, plant and equipment", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r32", "r33", "r34" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents", "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r29", "r186", "r1095" ] }, "us-gaap_CashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashAndCashEquivalentsLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Line Items]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r30" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents at end of year", "periodStartLabel": "Cash and cash equivalents at beginning of year", "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r29", "r100", "r232" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r1", "r100" ] }, "casi_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract", "presentation": [ "http://www.entremed.com/role/DisclosureLeasesSupplementalCashFlowDetails" ], "lang": { "en-us": { "role": { "label": "Cash paid for amounts included in the measurement of lease liabilities [Abstract]", "verboseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "auth_ref": [] }, "casi_CasiChinaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "CasiChinaMember", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPrecisionAutoimmuneTherapeuticsCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.entremed.com/role/DisclosureShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to CASI China.", "label": "Casi China [Member]", "terseLabel": "CASI China", "verboseLabel": "CASI China & Hongkong" } } }, "auth_ref": [] }, "casi_ChairmanAndChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ChairmanAndChiefExecutiveOfficerMember", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Person with designation of chairman and chief executive officer.", "label": "Chairman And Chief Executive Officer [Member]", "terseLabel": "Chairman and Chief Executive Officer" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r1286" ] }, "casi_ChinaNationalMedicinesCorporationLtd.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ChinaNationalMedicinesCorporationLtd.Member", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsChinaResourcesPharmaceuticalCommercialGroupInternationalTradingCoLtdDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to China National Medicines Corporation Ltd.", "label": "China National Medicines Corporation Ltd. [Member]", "terseLabel": "China National Medicines Corporation Ltd." } } }, "auth_ref": [] }, "casi_ChinaResourcesPharmaceuticalCommercialGroupInternationalTradingCo.Ltd.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ChinaResourcesPharmaceuticalCommercialGroupInternationalTradingCo.Ltd.Member", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsChinaResourcesPharmaceuticalCommercialGroupInternationalTradingCoLtdDetails", "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsRisksDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to China Resources Pharmaceutical Commercial Group International Trading Co., Ltd. (\"CRPCGIT\").", "label": "China Resources Pharmaceutical Commercial Group International Trading Co., Ltd. [Member]", "terseLabel": "China Resources Pharmaceutical Commercial Group International Trading Co., Ltd." } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r1283" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r1281" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfStockDomain", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails", "http://www.entremed.com/role/DisclosureShareBasedCompensationStockOptionOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r149", "r195", "r196", "r197", "r233", "r236", "r264", "r265", "r267", "r269", "r277", "r278", "r347", "r413", "r415", "r416", "r417", "r420", "r421", "r441", "r442", "r444", "r445", "r447", "r449", "r452", "r453", "r456", "r459", "r466", "r702", "r890", "r891", "r892", "r893", "r900", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r930", "r950", "r974", "r1062", "r1063", "r1064", "r1065", "r1066", "r1338", "r1384", "r1386", "r1395" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r195", "r196", "r197", "r277", "r444", "r452", "r453", "r454", "r456", "r459", "r464", "r466", "r659", "r890", "r891", "r892", "r893", "r1133", "r1338", "r1382", "r1384" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShareDetails", "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r1454" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShareDetails", "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Warrants outstanding, exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r233", "r239", "r467" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Each warrants issued for new share", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of warrants issued", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r467" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants outstanding (in shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "casi_CleaveTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "CleaveTherapeuticsIncMember", "presentation": [ "http://www.entremed.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsCleaveTherapeuticsIncDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueCleaveTherapeuticsIncDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Cleave Therapeutics, Inc.", "label": "Cleave Therapeutics Inc [Member]", "terseLabel": "Cleave Therapeutics, Inc" } } }, "auth_ref": [] }, "casi_ClinicalStudyServicePayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ClinicalStudyServicePayableCurrent", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of current portion of clinical study service payable as at the end of the reporting period.", "label": "Clinical Study Service Payable, Current", "terseLabel": "Payable to clinical study service" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r1287" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r1287" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies.", "verboseLabel": "Commitments and contingencies (Note 19)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r71", "r129", "r842", "r929" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r110", "r406", "r407", "r1076", "r1435", "r1440" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockMember", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsBioinventInternationalAbSummaryOfInvestmentsDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsSummaryOfLongTermInvestmentsDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r1215", "r1216", "r1217", "r1219", "r1220", "r1221", "r1222", "r1391", "r1392", "r1394", "r1511", "r1575", "r1585" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails", "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails", "http://www.entremed.com/role/DisclosureSubsequentEventsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par value (in dollars per share)", "verboseLabel": "Common Stock, Par Value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r74" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "verboseLabel": "Authorized common stock (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r74", "r930" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "verboseLabel": "Common Stock, Shares Issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r74" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Outstanding", "terseLabel": "Common Stock, Shares Outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r16", "r74", "r930", "r948", "r1585", "r1586" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "$0.0001 par value, 500,000,000 shares authorized 20,967,869 shares and 15,904,533 shares issued at December 31, 2025 and 2024, respectively; 20,555,873 shares and 15,492,581 shares outstanding at December 31, 2025 and 2024, respectively", "verboseLabel": "Ordinary shares", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r74", "r442", "r448", "r843", "r1199" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r1292" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r1291" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r1293" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r1290" ] }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureEmployeeBenefitPlan" ], "lang": { "en-us": { "role": { "label": "Compensation and Employee Benefit Plans [Text Block]", "terseLabel": "EMPLOYEE BENEFIT PLAN", "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": [ "r1456", "r1457", "r1458", "r1461" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "EMPLOYEE BENEFIT PLAN" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ComponentsOfDeferredTaxAssetsAbstract", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets [Abstract]", "terseLabel": "Deferred income tax assets:" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Deferred income tax assets and liabilities" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Liabilities [Abstract]", "terseLabel": "Deferred income tax liabilities:" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss attributable to ordinary shareholders", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r24", "r207", "r209", "r217", "r829", "r858", "r860" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Less: Comprehensive loss attributable to redeemable noncontrolling interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r9", "r51", "r55", "r207", "r209", "r216", "r828", "r858", "r859" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r55", "r123", "r207", "r209", "r215", "r827", "r858" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsRisksDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r280", "r307", "r883", "r884", "r1075", "r1398", "r1399", "r1400", "r1401", "r1402" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsRisksDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r280", "r307", "r883", "r884", "r1075", "r1398", "r1399", "r1400", "r1401", "r1402" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsRisksDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r280", "r307", "r883", "r884", "r1075", "r1398", "r1399", "r1400", "r1401", "r1402" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations Risks", "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument." } } }, "auth_ref": [ "r699", "r700" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsRisksDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r280", "r281", "r1075", "r1114", "r1398", "r1399", "r1400", "r1401", "r1402" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsRisksDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r280", "r307", "r1398", "r1399", "r1400", "r1401", "r1402" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsRisksDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": [ "r280", "r281", "r1075", "r1114", "r1398", "r1399", "r1400", "r1401", "r1402" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsRisksDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r280", "r307", "r883", "r884", "r1075", "r1398", "r1399", "r1400", "r1401", "r1402" ] }, "srt_CondensedBalanceSheetStatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CondensedBalanceSheetStatementTable", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Condensed Balance Sheet Statement [Table]", "documentation": "Disclosure of information about condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r150", "r234", "r244", "r835", "r1342" ] }, "srt_CondensedBalanceSheetStatementsCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CondensedBalanceSheetStatementsCaptionsLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Condensed Balance Sheet Statements, Captions [Line Items]", "terseLabel": "Condensed Balance Sheet Statements, Captions", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r150", "r234", "r244", "r835", "r1342" ] }, "srt_CondensedCashFlowStatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CondensedCashFlowStatementTable", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails" ], "lang": { "en-us": { "role": { "label": "Condensed Cash Flow Statement [Table]", "documentation": "Disclosure of information about condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r150", "r234", "r244", "r835", "r1342" ] }, "srt_CondensedCashFlowStatementsCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CondensedCashFlowStatementsCaptionsLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails" ], "lang": { "en-us": { "role": { "label": "Condensed Cash Flow Statements, Captions [Line Items]", "terseLabel": "Condensed Cash Flow Statements, Captions", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r150", "r234", "r244", "r835", "r1342" ] }, "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED FINANCIAL INFORMATION OF REGISTRANT" } } }, "auth_ref": [] }, "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrant" ], "lang": { "en-us": { "role": { "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]", "terseLabel": "CONDENSED FINANCIAL INFORMATION OF REGISTRANT", "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document." } } }, "auth_ref": [ "r234", "r244", "r835", "r1342" ] }, "srt_CondensedIncomeStatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CondensedIncomeStatementTable", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Condensed Income Statement [Table]", "documentation": "Disclosure of information about condensed income statement including, but not limited to, income statements of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r150", "r234", "r244", "r835", "r1342" ] }, "srt_CondensedIncomeStatementsCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CondensedIncomeStatementsCaptionsLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Condensed Income Statements, Captions [Line Items]", "terseLabel": "Condensed Income Statements, Captions", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r150", "r234", "r244", "r835", "r1342" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "documentation": "Information by consolidated entity or group of entities." } } }, "auth_ref": [ "r150", "r164", "r234", "r244", "r648", "r649", "r652", "r653", "r654", "r750", "r835", "r1081", "r1353", "r1354", "r1355", "r1443", "r1446", "r1447" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "documentation": "Entity or group of entities consolidated into reporting entity." } } }, "auth_ref": [ "r150", "r164", "r234", "r244", "r648", "r649", "r652", "r653", "r654", "r750", "r835", "r1081", "r1353", "r1354", "r1355", "r1443", "r1446", "r1447" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r53", "r1111" ] }, "dei_ContactPersonnelEmailAddress": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContactPersonnelEmailAddress", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Email Address", "documentation": "Email address of contact personnel." } } }, "auth_ref": [] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContactPersonnelName", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConvertibleDebtSecuritiesMember", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Securities [Member]", "terseLabel": "Convertible Note", "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder." } } }, "auth_ref": [ "r1459", "r1460" ] }, "casi_ConvertibleLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ConvertibleLoanMember", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to convertible loan.", "label": "Convertible Loan [Member]", "terseLabel": "Convertible loan" } } }, "auth_ref": [] }, "casi_ConvertibleNotesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ConvertibleNotesCurrent", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Current", "terseLabel": "Convertible notes due to a related party" } } }, "auth_ref": [] }, "casi_ConvertibleNotesTrancheFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ConvertibleNotesTrancheFourMember", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Tranche Four.", "label": "Convertible Notes Tranche Four [Member]", "terseLabel": "Tranche Four" } } }, "auth_ref": [] }, "casi_ConvertibleNotesTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ConvertibleNotesTrancheOneMember", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Tranche One.", "label": "Convertible Notes Tranche One [Member]", "terseLabel": "Tranche One" } } }, "auth_ref": [] }, "casi_ConvertibleNotesTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ConvertibleNotesTrancheThreeMember", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Tranche Three.", "label": "Convertible Notes Tranche Three [Member]", "terseLabel": "Tranche Three" } } }, "auth_ref": [] }, "casi_ConvertibleNotesTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ConvertibleNotesTrancheTwoMember", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Tranche Two.", "label": "Convertible Notes Tranche Two [Member]", "terseLabel": "Tranche Two" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Cost of Goods and Services Sold", "negatedLabel": "Costs of revenues", "terseLabel": "Costs of revenues", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r88", "r89", "r788", "r1105", "r1110", "r1183", "r1378" ] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CostOfSalesPolicyTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Costs of Revenues", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r1344" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Costs and Expenses", "negatedTotalLabel": "Total operating expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r95" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Operating expenses:", "verboseLabel": "Operating (expenses) income:" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.entremed.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBlackBeltTherapeuticsLimitedDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsChinaResourcesPharmaceuticalCommercialGroupInternationalTradingCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsCleaveTherapeuticsIncDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsGuangzhouGloriaBiosciencesCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsJuventasCellTherapyLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPharmathenGlobalBvDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsBioinventInternationalAbSummaryOfInvestmentsDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueCleaveTherapeuticsIncDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsSummaryOfLongTermInvestmentsDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsPurchaseOfOrdinarySharesDetails", "http://www.entremed.com/role/DisclosureSubsequentEventsDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r174", "r175", "r233", "r242", "r243", "r425", "r454", "r748", "r770", "r839", "r1101", "r1102", "r1103", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1506", "r1507", "r1508", "r1509" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CreditLossFinancialInstrumentPolicyTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Credit Loss, Financial Instrument [Policy Text Block]", "terseLabel": "Allowance for Credit Losses", "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status." } } }, "auth_ref": [ "r350", "r351", "r352", "r354", "r355", "r357", "r359", "r360", "r361", "r362", "r364", "r365", "r366", "r367", "r369", "r370", "r371", "r373" ] }, "casi_CurrentAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "CurrentAssetsNet", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount represent the surplus of a company's current assets over its current liabilities.", "label": "Current Assets, Net", "terseLabel": "Current assets, net" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsRisksDetails" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer concentration", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r307", "r1399" ] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1238", "r1327" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r1238", "r1327" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r1240", "r1329" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r1240", "r1329" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r1242", "r1331" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1240", "r1329" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r1233", "r1322" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r1234", "r1323" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r1234", "r1323" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r1232", "r1321" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r1232", "r1321" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r1232", "r1321" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r1235", "r1324" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r1237", "r1326" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r1237", "r1326" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1238", "r1327" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1241", "r1330" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r1239", "r1328" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r1236", "r1325" ] }, "us-gaap_DebtAndEquitySecuritiesRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtAndEquitySecuritiesRealizedGainLoss", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Debt and Equity Securities, Realized Gain (Loss)", "terseLabel": "Impairment loss of long-term investments", "documentation": "Amount of realized gain (loss) on investment in debt and equity securities." } } }, "auth_ref": [ "r959", "r960", "r1050", "r1051", "r1052", "r1375", "r1376" ] }, "casi_DebtAndEquitySecuritiesUnrealizedGainLossIncludingImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "DebtAndEquitySecuritiesUnrealizedGainLossIncludingImpairment", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsSummaryOfLongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in debt and equity securities including impairment charges.", "label": "Debt and Equity Securities, Unrealized Gain (Loss) Including Impairment", "terseLabel": "Gross unrealized losses (including impairment)" } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Exchange of redeemable noncontrolling interest to long term borrowing (Note 11)", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r32", "r34" ] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails" ], "lang": { "en-us": { "role": { "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Shares conversion", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": [ "r32", "r34" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r21", "r64", "r65", "r127", "r128", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r1127", "r1128", "r1129", "r1130", "r1131", "r1197", "r1382", "r1383", "r1385", "r1390", "r1436", "r1437", "r1438", "r1528", "r1529", "r1544" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r112", "r424" ] }, "casi_DebtInstrumentConvertibleVolumeWeightedAverageClosingPriceConsecutiveTradingDaysPrecedingMaturityDate": { "xbrltype": "integerItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "DebtInstrumentConvertibleVolumeWeightedAverageClosingPriceConsecutiveTradingDaysPrecedingMaturityDate", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of consecutive trading days immediately preceding the the maturity date regarding the volume weight average closing price to compute conversion price.", "label": "Debt Instrument, Convertible, Volume Weighted Average Closing Price, Consecutive Trading Days Preceding Maturity Date", "terseLabel": "Number of consecutive trading days" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount", "verboseLabel": "Aggregate Principal Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r422", "r721", "r722", "r1128", "r1129", "r1197" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails", "http://www.entremed.com/role/DisclosureShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate (as a percent)", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r67", "r423" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r21", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r1127", "r1128", "r1129", "r1130", "r1131", "r1197", "r1382", "r1383", "r1385", "r1390", "r1436", "r1437", "r1438", "r1528", "r1529", "r1544" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails", "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Term", "terseLabel": "Term of loan (in years)", "verboseLabel": "Loan term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtSecuritiesAvailableForSaleMeasurementInput", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsQuantitativeInformationAboutLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Measurement Input", "terseLabel": "Average/Median", "documentation": "Value of input used to measure investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r678", "r679", "r680", "r1189" ] }, "us-gaap_DebtSecuritiesAvailableForSaleMeasurementInputExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtSecuritiesAvailableForSaleMeasurementInputExtensibleList", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsQuantitativeInformationAboutLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Measurement Input [Extensible Enumeration]", "documentation": "Indicates measurement input for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r678" ] }, "us-gaap_DebtSecuritiesAvailableForSaleValuationTechniqueExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtSecuritiesAvailableForSaleValuationTechniqueExtensibleList", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsQuantitativeInformationAboutLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Valuation Technique [Extensible Enumeration]", "documentation": "Indicates valuation technique for measuring investment in debt security at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r678", "r1189" ] }, "casi_DebtSecuritiesConversionGainLossOnFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "DebtSecuritiesConversionGainLossOnFairValue", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on difference between the fair values of shares issued and the fair value of the convertible debt.", "label": "Debt Securities Conversion, Gain (Loss) On Fair Value", "terseLabel": "Debt securities conversion, gain (loss) on fair value" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtSecuritiesRealizedGainLoss", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueCleaveTherapeuticsIncDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Realized Gain (Loss)", "negatedLabel": "Gain from extinguishment of investment in a convertible loan", "terseLabel": "Gain from extinguishment of investment in a convertible loan", "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": [ "r863", "r1375", "r1376" ] }, "us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtSecuritiesTradingAndEquitySecuritiesFvNiCost", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsSummaryOfLongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Trading, and Equity Securities, FV-NI, Cost", "terseLabel": "Cost", "documentation": "Cost of investment in debt investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r1358" ] }, "casi_DeemedDividendsAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "DeemedDividendsAdjustment", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "documentation": "Amount of deemed dividend to subsidiary recognized from the difference between the present value of the Exchanged Liabilities and the carrying amount of the redeemable noncontrolling interest.", "label": "Deemed Dividends Adjustment", "terseLabel": "Deemed dividends to Wuxi LP", "verboseLabel": "Deemed Dividends Adjustment" } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]", "documentation": "Information by type of deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan." } } }, "auth_ref": [ "r47" ] }, "casi_DeferredTaxAssetsAccruedInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "DeferredTaxAssetsAccruedInterestExpense", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued interest expense.", "label": "Deferred Tax Assets, Accrued Interest Expense", "terseLabel": "Accrued interest expense" } } }, "auth_ref": [] }, "casi_DeferredTaxAssetsForeignCurrencyTranslationAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "DeferredTaxAssetsForeignCurrencyTranslationAdjustment", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax assets foreign currency translation adjustment.", "label": "Deferred Tax Assets Foreign Currency Translation Adjustment", "negatedLabel": "Foreign currency translation adjustment" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "verboseLabel": "Intangible assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill." } } }, "auth_ref": [ "r1496" ] }, "us-gaap_DeferredTaxAssetsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsInvestments", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Investments", "terseLabel": "Change in fair value of investments", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments)." } } }, "auth_ref": [ "r1496" ] }, "casi_DeferredTaxAssetsLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "DeferredTaxAssetsLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax assets, lease liabilities.", "label": "Deferred Tax Assets, Lease Liabilities", "terseLabel": "Lease liability" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net", "terseLabel": "Net deferred tax assets", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r1493" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred income tax assets", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1493" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards", "verboseLabel": "Net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r1496" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration", "terseLabel": "Operating loss carryforwards not subject to expiration", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates." } } }, "auth_ref": [ "r1496" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Other", "verboseLabel": "Others", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r1496" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "verboseLabel": "Research and development credit carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [ "r1496" ] }, "casi_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentAmortization", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized R&D amortization", "label": "Deferred Tax Assets, Tax Deferred Expense, Capitalized Research and Development Amortization", "terseLabel": "Capitalized R&D amortization" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "verboseLabel": "Share-based compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r1496" ] }, "casi_DeferredTaxAssetsTaxDeferredExpenseImpairmentLossOfLongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "DeferredTaxAssetsTaxDeferredExpenseImpairmentLossOfLongTermInvestments", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from impairment loss of long-term investments", "label": "Deferred Tax Assets, Tax Deferred Expense, Impairment Loss Of Long-term Investments", "terseLabel": "Impairment loss of long-term investments" } } }, "auth_ref": [] }, "casi_DeferredTaxAssetsTaxDeferredExpenseInventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "DeferredTaxAssetsTaxDeferredExpenseInventoryWriteDown", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from write down of inventory", "label": "Deferred Tax Assets, Tax Deferred Expense, Inventory Write Down", "terseLabel": "Write down of inventories" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails", "http://www.entremed.com/role/DisclosureIncomeTaxesValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance for deferred income tax assets", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r570" ] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net deferred income tax liabilities", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r1493" ] }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Other", "negatedLabel": "Others", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": [ "r1496" ] }, "casi_DeferredTaxLiabilitiesRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "DeferredTaxLiabilitiesRightOfUseAssets", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from deferred tax liabilities, right of use assets.", "label": "Deferred Tax Liabilities, Right Of Use Assets", "negatedLabel": "Right of use asset" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DefinedBenefitPlanContributionsByEmployer", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureEmployeeBenefitPlanDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Employer contributions", "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets." } } }, "auth_ref": [ "r477", "r479", "r486", "r487", "r491", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142" ] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureEmployeeBenefitPlanDetails" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Cost", "terseLabel": "Defined contribution plan expenses", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r492" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation for property, plant and equipment", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r11", "r37", "r222", "r1104", "r1105", "r1107", "r1109" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation expense", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r11", "r224", "r275", "r289", "r302", "r1104", "r1121", "r1122" ] }, "casi_DescriptionOfBusinessAndBasisOfPresentationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "DescriptionOfBusinessAndBasisOfPresentationLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBlackBeltTherapeuticsLimitedDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsChinaResourcesPharmaceuticalCommercialGroupInternationalTradingCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsCleaveTherapeuticsIncDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsGuangzhouGloriaBiosciencesCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsJuventasCellTherapyLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPharmathenGlobalBvDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPrecisionAutoimmuneTherapeuticsCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "documentation": "n/a.", "label": "Description of Business and Basis of Presentation [Line Items]", "terseLabel": "Description of Business and Basis of Presentation" } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "DirectorMember", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Director", "documentation": "Person serving on board of directors." } } }, "auth_ref": [ "r1356", "r1408", "r1582" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensation" ], "lang": { "en-us": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "verboseLabel": "SHARE-BASED COMPENSATION", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r494", "r498", "r529", "r530", "r532", "r1146" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "SHARE-BASED COMPENSATION" } } }, "auth_ref": [] }, "casi_DisclosureOfLeaseOnConsolidatedBalanceSheetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "DisclosureOfLeaseOnConsolidatedBalanceSheetTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of operating lease related assets and liabilities and other related information.", "label": "Disclosure of Lease on Consolidated Balance Sheet [Table Text Block]", "terseLabel": "Schedule of right of use assets and liabilities on condensed balance sheet" } } }, "auth_ref": [] }, "casi_DisclosureOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "DisclosureOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of operating lease related cash flow information.", "label": "Disclosure of Supplemental cash flow information related to leases [Table Text Block]", "terseLabel": "Schedule of supplemental cash flow information" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r181" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Held-for-Sale or Disposed of by sale, not discontinued operations", "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r6", "r12", "r20" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Disposal group, including discontinued operation, consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "casi_DisposalGroupOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "DisposalGroupOwnershipPercentage", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership in Disposal Group.", "label": "Disposal Group, Ownership Percentage", "terseLabel": "Disposal group, ownership percentage" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r402", "r403", "r1143", "r1144" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAccountingStandard", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r1230" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r1229", "r1230", "r1253" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r1229", "r1230", "r1253", "r1296" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationTable", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentRegistrationStatement", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r1226" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyReport", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r1230" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r1274" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DomesticCountryMember", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails", "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic Tax Authority", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": [ "r553" ] }, "casi_Dr.WeiWuHeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "Dr.WeiWuHeMember", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Dr. Wei-Wu He, one of the Company's board of directors", "label": "Dr. Wei Wu He [Member]", "terseLabel": "Dr. Wei Wu He" } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r1285" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "NET LOSS PER SHARE" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareComputationDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share (basic) (in $ per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r180", "r218", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r262", "r264", "r267", "r268", "r269", "r274", "r440", "r533", "r589", "r645", "r673", "r674", "r830", "r861", "r1113" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareComputationDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share (diluted) (in $ per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r180", "r218", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r264", "r267", "r268", "r269", "r274", "r440", "r533", "r589", "r645", "r673", "r674", "r830", "r861", "r1113" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r35", "r36", "r271" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "verboseLabel": "NET LOSS PER SHARE", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r261", "r270", "r272", "r273" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "verboseLabel": "Effect of exchange rate change on cash and cash equivalents", "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r1527" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective tax rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r553", "r1149" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]", "terseLabel": "Percent" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails", "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal statutory rate (as a percent)", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r233", "r238", "r553", "r579", "r1149" ] }, "casi_EffectiveIncomeTaxRateReconciliationAttributeExpirationAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "EffectiveIncomeTaxRateReconciliationAttributeExpirationAmount", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to expiration of tax attributes, such as net operating losses or tax credit carryforwards.", "label": "Effective Income Tax Rate Reconciliation, Attribute Expiration, Amount", "negatedLabel": "Attribute expiration" } } }, "auth_ref": [] }, "casi_EffectiveIncomeTaxRateReconciliationAttributeExpirationPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "EffectiveIncomeTaxRateReconciliationAttributeExpirationPercent", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to expiration of tax attributes, such as net operating losses or tax credit carryforwards.", "label": "Effective Income Tax Rate Reconciliation, Attribute Expiration, Percent", "terseLabel": "Attribute expiration" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r557", "r1149", "r1382", "r1389", "r1490" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationDeductions", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Deduction, Percent", "negatedLabel": "Research and development bonus deduction", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions." } } }, "auth_ref": [ "r1382", "r1389", "r1490", "r1491" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Tax rate differential", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": [ "r554", "r556", "r1149", "r1382", "r1389", "r1490" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation [Line Items]", "terseLabel": "INCOME TAXES", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r553", "r554", "r1149" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "terseLabel": "Nondeductible expenses", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r558", "r559", "r1382", "r1389", "r1490" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Others", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r1149", "r1382", "r1389", "r1490", "r1491" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount", "negatedLabel": "Tax shortfalls from share options", "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r1488", "r1490", "r1491" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent", "terseLabel": "Tax shortfalls from share options", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r1488", "r1490", "r1491" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationTable", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation [Table]", "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation." } } }, "auth_ref": [ "r553", "r554", "r1149" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShareDetails", "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [ "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1228" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityDomain", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPrecisionAutoimmuneTherapeuticsCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureGrantsDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails", "http://www.entremed.com/role/DisclosureLeasesDetails", "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.entremed.com/role/DisclosureShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1228" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1228" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1336" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1228" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1228" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r1337" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r1279" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r1332" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r1332" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r1332" ] }, "us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]", "documentation": "Deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan." } } }, "auth_ref": [ "r47" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquityComponentDomain", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsBioinventInternationalAbSummaryOfInvestmentsDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r16", "r178", "r179", "r180", "r211", "r212", "r213", "r245", "r246", "r247", "r249", "r256", "r258", "r260", "r276", "r348", "r349", "r400", "r439", "r468", "r533", "r577", "r578", "r586", "r587", "r588", "r590", "r644", "r645", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r672", "r713", "r714", "r715", "r716", "r717", "r719", "r723", "r725", "r741", "r856", "r874", "r875", "r876", "r900", "r974" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPrecisionAutoimmuneTherapeuticsCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r344", "r345", "r346", "r585", "r702", "r1339", "r1340", "r1341", "r1497", "r1498", "r1499", "r1500" ] }, "casi_EquityMethodInvestmentAggregateNumberOfInstallments": { "xbrltype": "integerItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "EquityMethodInvestmentAggregateNumberOfInstallments", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails" ], "lang": { "en-us": { "role": { "documentation": "Total number of installments in which the consideration for equity method investment will be paid.", "label": "Equity Method Investment, Aggregate Number Of Installments", "terseLabel": "Number of installments" } } }, "auth_ref": [] }, "casi_EquityMethodInvestmentInvestmentToBeMade": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "EquityMethodInvestmentInvestmentToBeMade", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Investment To Be Made", "label": "Investment to be made", "terseLabel": "Investment to be made" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails" ], "lang": { "en-us": { "role": { "label": "Equity Method Investment, Other than Temporary Impairment", "terseLabel": "Impairment of equity investment", "documentation": "Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting." } } }, "auth_ref": [ "r1419" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails" ], "lang": { "en-us": { "role": { "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity ownership (as a percent)", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r344", "r702" ] }, "casi_EquityMethodInvestmentOwnershipPercentageAcquiredDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "EquityMethodInvestmentOwnershipPercentageAcquiredDuringPeriod", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting obtained during the period.", "label": "Equity Method Investment, Ownership Percentage, Acquired During The Period", "terseLabel": "Equity method investment, ownership percentage" } } }, "auth_ref": [] }, "casi_EquityMethodInvestmentShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "EquityMethodInvestmentShares", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares invested under equity method investment.", "label": "Equity Method Investment, Shares", "terseLabel": "Number of new shares issued" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails" ], "lang": { "en-us": { "role": { "label": "Equity Method Investments", "terseLabel": "Investment", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r275", "r292", "r302", "r343", "r1357", "r1420" ] }, "casi_EquityMethodInvestmentsContribution": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "EquityMethodInvestmentsContribution", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of equity method investments contribution.", "label": "Equity Method Investments Contribution", "terseLabel": "Contribution amount" } } }, "auth_ref": [] }, "casi_EquityMethodInvestmentsExchangeOfCommonStocks": { "xbrltype": "sharesItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "EquityMethodInvestmentsExchangeOfCommonStocks", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued upon exchange.", "label": "Equity Method Investments Exchange of Common Stocks", "terseLabel": "Exchange of common stocks" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquitySecuritiesFvNiGainLoss", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 2.0 }, "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI, Gain (Loss)", "negatedLabel": "Change in fair value of investments", "terseLabel": "Change in fair value of investments", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r865", "r1418" ] }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquitySecuritiesFvNiRealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "terseLabel": "Recognized (losses) or gains", "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r863", "r1418" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsBioinventInternationalAbSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "verboseLabel": "Gross unrealized losses", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r864", "r1418" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsFinancialAndNonFinancialAssetsAndLiabilitiesDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsQuantitativeInformationAboutLevel3FairValueMeasurementsDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails" ], "lang": { "en-us": { "role": { "label": "Equity Securities without Readily Determinable Fair Value, Amount", "verboseLabel": "Investment in equity securities using measurement alternative, fair value", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r342" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r1289" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r1246", "r1257", "r1267", "r1300" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r1243", "r1254", "r1264", "r1297" ] }, "casi_EstimatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "EstimatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of estimated share-based compensation expense.", "label": "Estimated Share-Based Compensation Expense", "terseLabel": "Estimated share-based compensation expense" } } }, "auth_ref": [] }, "casi_EtpGlobalIiiFundLpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "EtpGlobalIiiFundLpMember", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to ETP Global III Fund LP.", "label": "ETP Global III Fund LP [Member]", "terseLabel": "ETP Global III" } } }, "auth_ref": [] }, "us-gaap_ExcessStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ExcessStockSharesAuthorized", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails" ], "lang": { "en-us": { "role": { "label": "Excess Stock, Shares Authorized", "terseLabel": "Additional shares of common stock purchase", "documentation": "Maximum number of excess stock shares permitted to be issued." } } }, "auth_ref": [] }, "casi_ExclusiveDistributionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ExclusiveDistributionAgreementMember", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsChinaResourcesPharmaceuticalCommercialGroupInternationalTradingCoLtdDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Exclusive Distribution Agreement.", "label": "Exclusive Distribution Agreement [Member]", "terseLabel": "Exclusive Distribution Agreement" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r1295" ] }, "us-gaap_ExtinguishmentOfDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ExtinguishmentOfDebtAmount", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsCleaveTherapeuticsIncDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueCleaveTherapeuticsIncDetails" ], "lang": { "en-us": { "role": { "label": "Extinguishment of Debt, Amount", "terseLabel": "Repayment of debt", "verboseLabel": "Principal amount", "documentation": "Gross amount of debt extinguished." } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Adjustment of Warrants", "terseLabel": "Fair value of the warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r11" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsFinancialAndNonFinancialAssetsAndLiabilitiesDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r676", "r677", "r687", "r1186" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsFinancialAndNonFinancialAssetsAndLiabilitiesDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r676", "r677", "r687", "r1186" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsQuantitativeInformationAboutLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r678", "r679", "r680", "r1150", "r1152", "r1189" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsQuantitativeInformationAboutLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r678", "r679", "r680", "r1150", "r1152", "r1189" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of quantitative information about level 3 fair value measurements", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r678", "r679", "r1189" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsFinancialAndNonFinancialAssetsAndLiabilitiesDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsQuantitativeInformationAboutLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r430", "r479", "r480", "r481", "r482", "r483", "r484", "r487", "r488", "r675", "r677", "r678", "r679", "r680", "r686", "r687", "r689", "r696", "r757", "r758", "r759", "r1092", "r1128", "r1129", "r1137", "r1138", "r1139", "r1140", "r1141", "r1186", "r1189", "r1196" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsFinancialAndNonFinancialAssetsAndLiabilitiesDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsQuantitativeInformationAboutLevel3FairValueMeasurementsDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r676", "r677", "r678", "r680", "r1186", "r1516", "r1519" ] }, "casi_FairValueCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "FairValueCarryingAmount", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The fair value carrying amount.", "label": "Fair Value Carrying Amount", "terseLabel": "Carrying amount" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "FAIR VALUE MEASUREMENTS" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "FAIR VALUE MEASUREMENTS", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r678", "r682", "r684", "r685", "r686", "r689", "r690", "r691", "r692", "r693", "r825", "r1186", "r1190" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsFinancialAndNonFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r430", "r479", "r484", "r487", "r677", "r687", "r696", "r757", "r1092", "r1137", "r1138", "r1139", "r1140", "r1141", "r1186", "r1196" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsFinancialAndNonFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r430", "r479", "r484", "r487", "r489", "r677", "r678", "r687", "r696", "r758", "r1092", "r1128", "r1129", "r1137", "r1138", "r1139", "r1140", "r1141", "r1186", "r1196" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsFinancialAndNonFinancialAssetsAndLiabilitiesDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsQuantitativeInformationAboutLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r430", "r479", "r480", "r481", "r482", "r483", "r484", "r487", "r488", "r677", "r678", "r679", "r680", "r687", "r696", "r759", "r1092", "r1128", "r1129", "r1137", "r1138", "r1139", "r1140", "r1141", "r1186", "r1189", "r1196" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsFinancialAndNonFinancialAssetsAndLiabilitiesDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsQuantitativeInformationAboutLevel3FairValueMeasurementsDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r676", "r677", "r678", "r680", "r1186", "r1516", "r1519" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsFinancialAndNonFinancialAssetsAndLiabilitiesDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsQuantitativeInformationAboutLevel3FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r430", "r479", "r480", "r481", "r482", "r483", "r484", "r487", "r488", "r675", "r677", "r678", "r679", "r680", "r686", "r687", "r689", "r696", "r757", "r758", "r759", "r1092", "r1128", "r1129", "r1137", "r1138", "r1139", "r1140", "r1141", "r1186", "r1189", "r1196" ] }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementsNonrecurringMember", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsFinancialAndNonFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Nonrecurring [Member]", "terseLabel": "Non-recurring", "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value." } } }, "auth_ref": [ "r676", "r677", "r678", "r680", "r1186", "r1516" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsFinancialAndNonFinancialAssetsAndLiabilitiesDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsQuantitativeInformationAboutLevel3FairValueMeasurementsDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r1186", "r1513", "r1514", "r1515", "r1516", "r1517", "r1519" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r1520" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsSummaryOfLongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r355", "r356", "r357", "r358", "r363", "r372", "r373", "r374", "r438", "r464", "r659", "r670", "r694", "r701", "r704", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r838", "r857", "r1126", "r1186", "r1187", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1200", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1414", "r1415", "r1416", "r1417", "r1512", "r1515", "r1516", "r1517", "r1518", "r1519", "r1521", "r1522" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Useful Life", "verboseLabel": "Estimated useful lives (in years)", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsNetDefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r190", "r379", "r390", "r1094" ] }, "casi_FiniteLivedIntangibleAssetsAccumulatedImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "FiniteLivedIntangibleAssetsAccumulatedImpairment", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsNetDefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Accumulated amount of impairment of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Impairment", "negatedLabel": "Impairment" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsExpectedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five", "verboseLabel": "2031 and thereafter", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1430", "r1587" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsExpectedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r392", "r1090", "r1094" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]", "terseLabel": "Schedule of net definite-lived intangible assets", "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsExpectedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "verboseLabel": "2030", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r392", "r1090", "r1094" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsExpectedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2029", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r392", "r1090", "r1094" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsExpectedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r392", "r1090", "r1094" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsExpectedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r392", "r1090", "r1094" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsDetails", "http://www.entremed.com/role/DisclosureIntangibleAssetsNarrativesDetails", "http://www.entremed.com/role/DisclosureIntangibleAssetsNetDefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r382", "r384", "r385", "r386", "r389", "r390", "r393", "r394", "r789", "r790", "r882", "r1090", "r1094", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180" ] }, "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsIntangibleAssetsRollforwardDetails" ], "lang": { "en-us": { "role": { "label": "Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss)", "negatedLabel": "Foreign currency translation adjustment", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsNarrativesDetails", "http://www.entremed.com/role/DisclosureIntangibleAssetsNetDefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Cost of intangible assets", "verboseLabel": "Purchase Price", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r379", "r390", "r790", "r1094" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsNarrativesDetails", "http://www.entremed.com/role/DisclosureIntangibleAssetsNetDefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r382", "r390", "r393", "r394", "r398", "r789", "r1090", "r1094", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsDetails", "http://www.entremed.com/role/DisclosureIntangibleAssetsNarrativesDetails", "http://www.entremed.com/role/DisclosureIntangibleAssetsNetDefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r382", "r384", "r385", "r386", "r389", "r390", "r393", "r394", "r882", "r1090", "r1094", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsIntangibleAssetsRollforwardDetails", "http://www.entremed.com/role/DisclosureIntangibleAssetsNetDefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "periodEndLabel": "Balance at the ending of the year", "periodStartLabel": "Balance at the beginning of the year", "terseLabel": "Carrying Amount", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r789", "r1429" ] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Finite-lived intangible assets, remaining amortization period", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r789" ] }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FinitelivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsIntangibleAssetsRollforwardDetails" ], "lang": { "en-us": { "role": { "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Addition", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." } } }, "auth_ref": [ "r384", "r882" ] }, "casi_FolotynMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "FolotynMember", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsDetails", "http://www.entremed.com/role/DisclosureIntangibleAssetsNarrativesDetails", "http://www.entremed.com/role/DisclosureIntangibleAssetsNetDefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to FOLOTYN.", "label": "FOLOTYN [Member]", "terseLabel": "License of FOLOTYN", "verboseLabel": "FOLOTYN" } } }, "auth_ref": [] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ForeignCountryMember", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails", "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Tax Authority", "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile." } } }, "auth_ref": [ "r553", "r554" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "Foreign exchange gain (loss)", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r221", "r707", "r709", "r710", "r712", "r971" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation and Transactions", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r706" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r1250", "r1261", "r1271", "r1304" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r1250", "r1261", "r1271", "r1304" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r1250", "r1261", "r1271", "r1304" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r1250", "r1261", "r1271", "r1304" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1250", "r1261", "r1271", "r1304" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r1284" ] }, "casi_FullyDilutedCapitalPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "FullyDilutedCapitalPercentage", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the fully diluted capital.", "label": "Fully Diluted Capital Percentage", "terseLabel": "Percentage of fully diluted capital" } } }, "auth_ref": [] }, "casi_FurnitureAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "FurnitureAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentByTypeDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentByTypeDetails" ], "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of long-lived, depreciable assets used in the production process to produce goods and services and commonly used in offices and stores.", "label": "Furniture And Equipment Gross", "verboseLabel": "Office equipment and furniture" } } }, "auth_ref": [] }, "casi_FurnitureAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "FurnitureAndEquipmentMember", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPpeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information related to furniture and equipment.", "label": "Furniture And Equipment [Member]", "terseLabel": "Office equipment and furniture" } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Assets", "verboseLabel": "Gain on disposal of long-lived assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r1379" ] }, "us-gaap_GainLossOnDispositionOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GainLossOnDispositionOfIntangibleAssets", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Intangible Assets", "negatedLabel": "(Gain) loss on disposal of long-lived assets", "documentation": "Amount of gain (loss) on sale or disposal of intangible assets." } } }, "auth_ref": [ "r1379" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense.", "negatedLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r93", "r953" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r93" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "INTANGIBLE ASSETS" } } }, "auth_ref": [] }, "casi_GovernmentGrantsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "GovernmentGrantsPolicyTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for government grants.", "label": "Government Grants [Policy Text Block]", "terseLabel": "Government Grants" } } }, "auth_ref": [] }, "casi_GrantsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "GrantsDisclosureAbstract", "lang": { "en-us": { "role": { "documentation": "Grants, Disclosure [Abstract]", "label": "GRANTS" } } }, "auth_ref": [] }, "casi_GrantsDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "GrantsDisclosureLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureGrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Grants, Disclosure [Line Items]", "terseLabel": "Grants" } } }, "auth_ref": [] }, "casi_GrantsDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "GrantsDisclosureTable", "presentation": [ "http://www.entremed.com/role/DisclosureGrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information pertaining to grants receivable or received by the company.", "label": "Grants, Disclosure [Table]" } } }, "auth_ref": [] }, "casi_GrantsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "GrantsDisclosureTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureGrants" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for grants receivable or received by the company.", "label": "Grants, Disclosure [Text Block]", "verboseLabel": "GRANTS" } } }, "auth_ref": [] }, "casi_GrantsEligible": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "GrantsEligible", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureGrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This information is pertaining to the amount of grants eligible.", "label": "Grants Eligible", "terseLabel": "Amount of grants eligible" } } }, "auth_ref": [] }, "casi_GrantsRelatedToLandUseRightCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "GrantsRelatedToLandUseRightCurrent", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of current portion of grants related to land use right.", "label": "Grants Related to Land use Right, Current", "terseLabel": "Grants related to land use right" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Gross Profit", "totalLabel": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r84", "r90", "r137", "r233", "r235", "r236", "r347", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r702", "r1117", "r1121", "r1397", "r1404", "r1405", "r1406", "r1407", "r1444" ] }, "casi_GuangzhouGloriaBiosciencesCo.Ltd.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "GuangzhouGloriaBiosciencesCo.Ltd.Member", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsGuangzhouGloriaBiosciencesCoLtdDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to Guangzhou Gloria Biosciences Co., Ltd.", "label": "Guangzhou Gloria Biosciences Co., Ltd. [Member]", "terseLabel": "Guangzhou Gloria Biosciences Co., Ltd." } } }, "auth_ref": [] }, "country_HK": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "HK", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails", "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails", "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "HONG KONG", "terseLabel": "HONG KONG", "verboseLabel": "Hong Kong" } } }, "auth_ref": [] }, "casi_HeFamilyGratMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "HeFamilyGratMember", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to HE family GRAT, a grantor retained annuity trust for the benefit of CEO's family members.", "label": "He Family GRAT [Member]", "terseLabel": "He Family GRAT" } } }, "auth_ref": [] }, "casi_HuiyingMemorialFoundationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "HuiyingMemorialFoundationMember", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsPurchaseOfOrdinarySharesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Huiying Memorial Foundation.", "label": "Huiying Memorial Foundation [Member]", "terseLabel": "Huiying Memorial Foundation" } } }, "auth_ref": [] }, "casi_HumanLongevityIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "HumanLongevityIncMember", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Human Longevity Inc.", "label": "Human Longevity Inc [Member]", "terseLabel": "Human Longevity Inc" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r1229", "r1230", "r1253" ] }, "us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of intangible asset. Includes, but is not limited to, finite-lived and indefinite-lived intangible assets." } } }, "auth_ref": [ "r397" ] }, "casi_ImpairmentLossOfLongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ImpairmentLossOfLongTermInvestments", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss of long-term investments.", "label": "Impairment Loss of Long-term Investments", "negatedLabel": "Impairment loss of long-term investments" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Impairment of intangible assets", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value." } } }, "auth_ref": [ "r11", "r220", "r383", "r396" ] }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 }, "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsIntangibleAssetsRollforwardDetails", "http://www.entremed.com/role/DisclosureIntangibleAssetsNarrativesDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Impairment of Intangible Assets, Finite-lived", "negatedLabel": "Impairment", "negatedTerseLabel": "Impairment of intangible assets", "verboseLabel": "Impairment of intangible assets", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": [ "r383", "r1379", "r1434" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r109" ] }, "us-gaap_InProcessResearchAndDevelopmentPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InProcessResearchAndDevelopmentPolicy", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "In Process Research and Development, Policy [Policy Text Block]", "terseLabel": "Acquired In-Process Research and Development Expense", "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets." } } }, "auth_ref": [] }, "casi_IncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsNoncontrollingInterestAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "IncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsNoncontrollingInterestAfterTax", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, attributable to noncontrolling interest, and addition of income (loss) from equity method investments net of tax.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Noncontrolling Interest, After Tax", "totalLabel": "Net loss before share of net loss in an equity investee" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "verboseLabel": "United States", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r233", "r237", "r552" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Loss before income tax expense", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r85", "r133", "r137", "r831", "r833", "r853", "r1106", "r1108", "r1110", "r1117", "r1121", "r1397", "r1404", "r1405", "r1406", "r1407" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "verboseLabel": "Mainland China and Hong Kong", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r233", "r237", "r552" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "casi_IncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsNoncontrollingInterestAfterTax", "weight": 1.0, "order": 2.0 }, "http://www.entremed.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income tax benefit and share of net loss in an equity investee", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": [ "r137", "r868", "r1117", "r1213", "r1214", "r1397", "r1404", "r1405", "r1406", "r1407" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Equity Method Investments", "negatedLabel": "Share of net loss of an equity investee", "terseLabel": "Share of net loss in an equity investee", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r11", "r86", "r132", "r275", "r290", "r302", "r343", "r852" ] }, "us-gaap_IncomeLossFromSubsidiariesBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromSubsidiariesBeforeTax", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Subsidiaries, before Tax", "terseLabel": "Share of loss of subsidiaries", "documentation": "Amount before tax of income (loss) of subsidiary attributable to the parent entity." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Operations and Comprehensive Loss" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r402", "r403", "r1143", "r1144" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPharmathenGlobalBvDetails", "http://www.entremed.com/role/DisclosureShareBasedCompensationCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in statement of income where disaggregated amount is reported." } } }, "auth_ref": [ "r401", "r404", "r405", "r655", "r656", "r657", "r658", "r681", "r683", "r688", "r703", "r704", "r705", "r871", "r873", "r958", "r1090", "r1092", "r1150", "r1151", "r1184", "r1185", "r1188", "r1196", "r1501", "r1503", "r1547" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPharmathenGlobalBvDetails", "http://www.entremed.com/role/DisclosureShareBasedCompensationCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in statement of income where disaggregated amount is reported." } } }, "auth_ref": [ "r404", "r405", "r655", "r656", "r657", "r658", "r681", "r683", "r688", "r703", "r704", "r705", "r871", "r873", "r958", "r1090", "r1092", "r1150", "r1151", "r1184", "r1185", "r1188", "r1196", "r1501", "r1503", "r1547" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails", "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r231", "r553", "r554", "r564", "r574", "r1149", "r1495" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails", "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r231", "r553", "r554", "r564", "r574", "r1149", "r1495" ] }, "us-gaap_IncomeTaxContingencyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxContingencyLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Tax Contingency", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxContingencyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxContingencyTable", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Contingency [Table]", "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": [ "r1492" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "INCOME TAXES" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "INCOME TAXES", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r233", "r238", "r547", "r553", "r560", "r561", "r562", "r567", "r572", "r580", "r582", "r583", "r584", "r837", "r881", "r895", "r1149" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "casi_IncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsNoncontrollingInterestAfterTax", "weight": -1.0, "order": 1.0 }, "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails", "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax benefit", "negatedTerseLabel": "Income tax expense", "negatedTotalLabel": "Total", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r140", "r147", "r233", "r259", "r260", "r275", "r291", "r302", "r551", "r553", "r581", "r869", "r1106", "r1108", "r1110", "r1149" ] }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]", "terseLabel": "Amount" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r210", "r549", "r550", "r567", "r568", "r571", "r576", "r889" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "negatedLabel": "Change in valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r557", "r1149", "r1490" ] }, "us-gaap_IncomeTaxReconciliationDeductions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationDeductions", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Deduction, Amount", "terseLabel": "Research and development bonus deduction", "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions." } } }, "auth_ref": [ "r1490", "r1491" ] }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "negatedLabel": "Tax rate differential", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)." } } }, "auth_ref": [ "r554", "r556", "r1149", "r1490" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "negatedLabel": "Tax benefit at statutory federal rate", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r553", "r1149" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationNondeductibleExpense", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount", "negatedLabel": "Nondeductible expenses", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r558", "r559", "r1490" ] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "negatedLabel": "Others", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r1149", "r1490", "r1491" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income Taxes Paid, Net", "verboseLabel": "Income taxes paid", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r31", "r231", "r573", "r574" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Accounts payable", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income tax payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued liabilities and other liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r10" ] }, "casi_IncreaseDecreaseInDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "IncreaseDecreaseInDeferredTaxAssets", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of increase decrease in deferred tax assets.", "label": "Increase Decrease In Deferred Tax Assets", "terseLabel": "Additions" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInDueFromRelatedPartiesCurrent", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Due from Related Parties, Current", "negatedLabel": "Receivable from a related party", "documentation": "The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsDetails", "http://www.entremed.com/role/DisclosureFairValueMeasurementsFinancialAndNonFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure", "terseLabel": "Intangible assets, fair value", "documentation": "Fair value portion of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit." } } }, "auth_ref": [ "r1513", "r1514", "r1518", "r1524" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r1250", "r1261", "r1271", "r1295", "r1304", "r1308", "r1316" ] }, "casi_InitialCashInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "InitialCashInvestment", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "documentation": "Initial cash investment.", "label": "Initial Cash Investment", "terseLabel": "Initial cash investment" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r1314" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r1231", "r1320" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r1231", "r1320" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r1231", "r1320" ] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Intangible Assets Disclosure [Text Block]", "verboseLabel": "INTANGIBLE ASSETS", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r381", "r395", "r399", "r1089", "r1090" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill)", "verboseLabel": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r382", "r1429", "r1431" ] }, "casi_IntercompanyOperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "IntercompanyOperatingExpenses", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of operating expenses from intercompany transactions during the reporting period.", "label": "Intercompany Operating Expenses", "terseLabel": "Intercompany expenses" } } }, "auth_ref": [] }, "casi_IntercompanyPayablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "IntercompanyPayablesCurrent", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of intercompany payables, payable within one year or the normal operating cycle, if longer.", "label": "Intercompany Payables, Current", "terseLabel": "Intercompany payables" } } }, "auth_ref": [] }, "casi_IntercompanyReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "IntercompanyReceivables", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of intercompany receivables as of the balance sheet date.", "label": "Intercompany Receivables", "terseLabel": "Intercompany receivables" } } }, "auth_ref": [] }, "casi_InterestAndDividendsPayableNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "InterestAndDividendsPayableNonCurrent", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of (a) interest payable on all forms of debt, including trade payables, that has been incurred, and (b) dividends declared but unpaid on equity securities issued by the entity and outstanding (also includes dividends collected on behalf of another owner of securities that are being held by the entity). Used to reflect the non-current portion of the liabilities (due within more than 12 month, or the operating cycle if longer).", "label": "Interest And Dividends Payable Non Current", "terseLabel": "Dividends and interest payable to Wuxi LP, non current (Note 11)" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Interest Income (Expense), Net", "terseLabel": "Interest expense", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": [ "r1121", "r1183", "r1377", "r1404" ] }, "us-gaap_InterestIncomeOperatingAndNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestIncomeOperatingAndNonoperating", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Interest Income, Operating and Nonoperating", "terseLabel": "Interest income", "documentation": "Amount of interest income classified as operating and nonoperating." } } }, "auth_ref": [ "r288", "r1121" ] }, "casi_InterestLoanPrincipalAndDividendsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "InterestLoanPrincipalAndDividendsPayableCurrent", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of (a) interest payable on all forms of debt, including trade payables, that has been incurred, and (b) loan principal payable (c) dividends declared but unpaid on equity securities issued by the entity and outstanding (also includes dividends collected on behalf of another owner of securities that are being held by the entity). Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Loan Principal And Dividends Payable Current", "terseLabel": "Dividends and interest payable to Wuxi LP, current (Note 11)" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "verboseLabel": "Interest paid", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r225", "r229", "r230" ] }, "casi_InterestRateOnEquityConsiderationPayable": { "xbrltype": "percentItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "InterestRateOnEquityConsiderationPayable", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The rate of interest that was being paid on certain investments calculated from the date of investment through the date of payment of aggregate equity consideration.", "label": "Interest Rate On Equity Consideration Payable", "terseLabel": "Interest Rate" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "INVENTORIES" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureInventories" ], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "verboseLabel": "INVENTORIES", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r375" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureInventoriesScheduleOfInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureInventoriesScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r104", "r1098" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.entremed.com/role/DisclosureInventoriesScheduleOfInventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/DisclosureInventoriesDetails", "http://www.entremed.com/role/DisclosureInventoriesScheduleOfInventoryDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r201", "r1096", "r1199" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r141", "r185", "r200", "r375", "r376", "r378", "r787", "r1112" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureInventoriesScheduleOfInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureInventoriesScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r104", "r1100" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosureInventoriesScheduleOfInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureInventoriesScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in progress", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r104", "r1099" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureInventoriesDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Inventory write down", "terseLabel": "Write down of obsolete inventories", "verboseLabel": "Write-down of inventories", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r377" ] }, "casi_InvestmentCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "InvestmentCommitment", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the investment commitment.", "label": "Investment Commitment", "terseLabel": "Investment commitment" } } }, "auth_ref": [] }, "casi_InvestmentEquitySecuritiesFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "InvestmentEquitySecuritiesFairValue", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value.", "label": "Investment Equity Securities, Fair Value", "terseLabel": "Investment in equity securities, at fair value" } } }, "auth_ref": [] }, "us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsTables" ], "lang": { "en-us": { "role": { "label": "Investment Holdings, Schedule of Investments [Table Text Block]", "terseLabel": "Schedule of investments in equity securities", "documentation": "Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments." } } }, "auth_ref": [ "r1576", "r1577", "r1578", "r1579", "r1580", "r1581" ] }, "us-gaap_InvestmentHoldingsScheduleOfInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentHoldingsScheduleOfInvestmentsTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestments" ], "lang": { "en-us": { "role": { "label": "Investment Holdings, Schedule of Investments [Text Block]", "verboseLabel": "INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS", "documentation": "The entire disclosure for investments owned by investment company." } } }, "auth_ref": [ "r913", "r982", "r983", "r984", "r1001", "r1018", "r1028", "r1057" ] }, "casi_InvestmentInConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "InvestmentInConvertibleNote", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueCleaveTherapeuticsIncDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of investment in convertible note.", "label": "Investment in Convertible Note", "terseLabel": "Investment in convertible note" } } }, "auth_ref": [] }, "casi_InvestmentInSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "InvestmentInSubsidiaries", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of investments in subsidiaries as at the end of the reporting period.", "label": "Investment in Subsidiaries", "terseLabel": "Investment in subsidiaries" } } }, "auth_ref": [] }, "us-gaap_InvestmentOwnedAtCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentOwnedAtCost", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsBioinventInternationalAbSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Available-for-sale Equity Securities, Amortized Cost Basis", "verboseLabel": "Cost", "documentation": "Cost of the investment." } } }, "auth_ref": [ "r885", "r917", "r918", "r997", "r1007", "r1024", "r1057", "r1217", "r1225", "r1579" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r862", "r885", "r886", "r887", "r888", "r1004", "r1006" ] }, "casi_InvestmentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "InvestmentPrincipal", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of investment principal made by the entity.", "label": "Investment Principal", "terseLabel": "Investment principal" } } }, "auth_ref": [] }, "casi_InvestmentPrincipalReturned": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "InvestmentPrincipalReturned", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of investment principal returned.", "label": "Investment Principal Returned", "terseLabel": "Investment principal returned" } } }, "auth_ref": [] }, "casi_InvestmentReturnPayableAsDividendNumberOfInstallments": { "xbrltype": "integerItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "InvestmentReturnPayableAsDividendNumberOfInstallments", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of installments in which carrying value as of the balance sheet date of investment return payable as a dividend.", "label": "Investment Return Payable as A Dividend, Number of Installments", "terseLabel": "Number of installments in which investment is paid" } } }, "auth_ref": [] }, "casi_InvestmentReturnPayableAsDividendYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "InvestmentReturnPayableAsDividendYearFour", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of investment return payable as a dividend of year four.", "label": "Investment Return Payable as A Dividend, Year Four", "terseLabel": "Dividend payable, installment four" } } }, "auth_ref": [] }, "casi_InvestmentReturnPayableAsDividendYearOne": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "InvestmentReturnPayableAsDividendYearOne", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of investment return payable as a dividend.", "label": "Investment Return Payable as A Dividend, Year One", "terseLabel": "Dividend payable, installment one" } } }, "auth_ref": [] }, "casi_InvestmentReturnPayableAsDividendYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "InvestmentReturnPayableAsDividendYearThree", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of investment return payable as a dividend of year three.", "label": "Investment Return Payable as A Dividend, Year Three", "terseLabel": "Dividend payable, installment three" } } }, "auth_ref": [] }, "casi_InvestmentReturnPayableAsDividendYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "InvestmentReturnPayableAsDividendYearTwo", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of investment return payable as a dividend of year two.", "label": "Investment Return Payable as A Dividend, Year Two", "terseLabel": "Dividend payable, installment two" } } }, "auth_ref": [] }, "casi_InvestmentReturnPayableInInstallments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "InvestmentReturnPayableInInstallments", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of investment return payable in installments.", "label": "Investment Return Payable in Installments", "terseLabel": "Investment return in installments" } } }, "auth_ref": [] }, "us-gaap_InvestmentTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentTypeExtensibleEnumeration", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsSummaryOfLongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Type [Extensible Enumeration]", "documentation": "Indicates type of investment. Includes, but is not limited to, common stock, preferred stock, convertible security, fixed income security, government security, option purchased, warrant, loan participation and assignment, commercial paper, bankers' acceptance, certificates of deposit, short-term security, repurchase agreement, and other investment company." } } }, "auth_ref": [ "r914", "r917", "r985", "r993", "r1008", "r1009", "r1010", "r1031", "r1046", "r1058" ] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsBioinventInternationalAbSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Investments, Fair Value Disclosure", "verboseLabel": "Equity securities at fair value", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": [ "r1513", "r1514", "r1518", "r1521", "r1522", "r1523", "r1525" ] }, "casi_InvestmentsFairValueDisclosureEquitySecuritiesInOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "InvestmentsFairValueDisclosureEquitySecuritiesInOrdinaryShares", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsFinancialAndNonFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of investments fair value disclosure of equity securities in ordinary shares.", "label": "Investments, Fair Value Disclosure, Equity Securities in Ordinary Shares", "terseLabel": "Investment in ordinary shares" } } }, "auth_ref": [] }, "casi_InvestmentsFairValueDisclosureWarrantsMeasuredAtFairValueThroughProfitAndLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "InvestmentsFairValueDisclosureWarrantsMeasuredAtFairValueThroughProfitAndLoss", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsFinancialAndNonFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of Investments fair value disclosure warrants measured at fair value through profit and loss.", "label": "Investments Fair Value Disclosure Warrants Measured At Fair Value Through Profit And Loss", "terseLabel": "Investment in warrants - Designated as investment measured at FVTPL" } } }, "auth_ref": [] }, "casi_July2024PrivateInvestmentInPublicEquityFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "July2024PrivateInvestmentInPublicEquityFinancingMember", "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShareDetails", "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to July 2024 PIPE transaction.", "label": "July 2024 Private Investment in Public Equity Financing [Member]", "terseLabel": "2024 PIPE transaction" } } }, "auth_ref": [] }, "casi_JuventasCellTherapyLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "JuventasCellTherapyLtdMember", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsJuventasCellTherapyLtdDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to Juventas Cell Therapy Ltd.", "label": "Juventas Cell Therapy Ltd [Member]", "terseLabel": "Juventas Cell Therapy Ltd." } } }, "auth_ref": [] }, "casi_KaixinPharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "KaixinPharmaceuticalsIncMember", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Kaixin Pharmaceuticals Inc. (\"Kaixin Pharmaceuticals\").", "label": "Kaixin Pharmaceuticals Inc [Member]", "terseLabel": "Kaixin Pharmaceuticals Inc" } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeaseContractualTermAxis", "presentation": [ "http://www.entremed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r739", "r1343" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeaseContractualTermDomain", "presentation": [ "http://www.entremed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r739", "r1343" ] }, "us-gaap_LeaseholdImprovementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeaseholdImprovementsGross", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentByTypeDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentByTypeDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements, Gross", "verboseLabel": "Leasehold improvements", "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r106" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "LEASES" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LegalEntityAxis", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPrecisionAutoimmuneTherapeuticsCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureGrantsDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails", "http://www.entremed.com/role/DisclosureLeasesDetails", "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.entremed.com/role/DisclosureShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r730" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of future undiscounted cash flows", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1530" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureLeasesFutureUndiscountedCashFlowsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.entremed.com/role/DisclosureLeasesFutureUndiscountedCashFlowsDetailsCalc2": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.entremed.com/role/DisclosureLeasesFutureUndiscountedCashFlowsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r737", "r1383", "r1390", "r1544" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureLeasesFutureUndiscountedCashFlowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureLeasesFutureUndiscountedCashFlowsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments Receivable, Current", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r737", "r1383", "r1390", "r1544" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureLeasesFutureUndiscountedCashFlowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureLeasesFutureUndiscountedCashFlowsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2029", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r737", "r1383", "r1390", "r1544" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureLeasesFutureUndiscountedCashFlowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureLeasesFutureUndiscountedCashFlowsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "verboseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r737", "r1383", "r1390", "r1544" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureLeasesFutureUndiscountedCashFlowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureLeasesFutureUndiscountedCashFlowsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r737", "r1383", "r1390", "r1544" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureLeasesFutureUndiscountedCashFlowsDetailsCalc2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureLeasesFutureUndiscountedCashFlowsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Discount factor", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r737" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureLeases" ], "lang": { "en-us": { "role": { "label": "Leases of Lessee Disclosure [Text Block]", "verboseLabel": "LEASES", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r724" ] }, "us-gaap_LessorLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LessorLeaseDescriptionLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessor, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r740" ] }, "us-gaap_LessorLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LessorLeaseDescriptionTable", "presentation": [ "http://www.entremed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessor, Lease, Description [Table]", "documentation": "Disclosure of information about lessor's leases." } } }, "auth_ref": [ "r740" ] }, "us-gaap_LessorOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LessorOperatingLeaseTermOfContract", "presentation": [ "http://www.entremed.com/role/DisclosureGrantsDetails", "http://www.entremed.com/role/DisclosureLeasesDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Lessor, Operating Lease, Term of Contract", "terseLabel": "Term of lease contract", "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1531" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r21", "r64", "r65", "r66", "r69", "r70", "r71", "r72", "r233", "r235", "r236", "r347", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r649", "r653", "r654", "r702", "r928", "r1116", "r1132", "r1225", "r1444", "r1535", "r1536" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' (deficit) equity", "verboseLabel": "Total liabilities and shareholders' (deficit) equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r79", "r131", "r847", "r1199", "r1213", "r1214", "r1382", "r1387", "r1421", "r1526" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r66", "r184", "r233", "r235", "r236", "r347", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r649", "r653", "r654", "r702", "r1199", "r1444", "r1535", "r1536" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities", "terseLabel": "Liabilities of disposal group including discontinued operation", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r2", "r58", "r60", "r108", "r181", "r182" ] }, "casi_LicenseAgreementAggregateAmountPayableInQuarterlyInstallment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "LicenseAgreementAggregateAmountPayableInQuarterlyInstallment", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "documentation": "The aggregate amount payable in quarterly installments under the license agreement.", "label": "License Agreement, Aggregate Amount Payable in Quarterly Installment", "terseLabel": "License agreement, aggregate amount payable in quarterly installment" } } }, "auth_ref": [] }, "casi_LicenseAgreementAmountPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "LicenseAgreementAmountPayable", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount payable under the license agreement.", "label": "License Agreement, Amount Payable", "terseLabel": "License agreement, amount payable" } } }, "auth_ref": [] }, "casi_LicenseAgreementAmountPayableOnCompletionOfAuditAndDeferredQuarterlyPaymentsBecomesDueImmediatelyUponEventOfNonPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "LicenseAgreementAmountPayableOnCompletionOfAuditAndDeferredQuarterlyPaymentsBecomesDueImmediatelyUponEventOfNonPayment", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount payable becomes due immediately upon event of non payment of one time payment payable upon completion of quality and quarterly installments under the license agreement.", "label": "License Agreement, Amount Payable on Completion of Audit and Deferred Quarterly Payments Becomes Due Immediately Upon Event of Non Payment", "terseLabel": "License agreement, amount payable on completion of audit and deferred quarterly payments becomes due immediately upon event of non payment" } } }, "auth_ref": [] }, "casi_LicenseAgreementDevelopmentMilestonePaymentPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "LicenseAgreementDevelopmentMilestonePaymentPayable", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBlackBeltTherapeuticsLimitedDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of development milestone payment payment payable under the license agreement.", "label": "License Agreement, Development Milestone Payment Payable", "terseLabel": "Development milestone payable" } } }, "auth_ref": [] }, "casi_LicenseAgreementMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "LicenseAgreementMilestonePayment", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBlackBeltTherapeuticsLimitedDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsCleaveTherapeuticsIncDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsJuventasCellTherapyLtdDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of milestone payment under license agreement.", "label": "License Agreement, Milestone Payment", "terseLabel": "Milestone payment" } } }, "auth_ref": [] }, "casi_LicenseAgreementOneTimePaymentPayableUponCompletionOfQualityAudit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "LicenseAgreementOneTimePaymentPayableUponCompletionOfQualityAudit", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of one time payment payable upon completion of quality audit under the license agreement.", "label": "License Agreement, One Time Payment, Payable Upon Completion of Quality Audit", "terseLabel": "License agreement, one time payment, payable upon completion of quality audit" } } }, "auth_ref": [] }, "casi_LicenseAgreementRefundFromTerminationOfAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "LicenseAgreementRefundFromTerminationOfAgreement", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPharmathenGlobalBvDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of refund received from termination of license agreement", "label": "License Agreement, Refund from Termination of Agreement", "terseLabel": "License agreement refunded" } } }, "auth_ref": [] }, "casi_LicenseAgreementSalesMilestonePaymentPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "LicenseAgreementSalesMilestonePaymentPayable", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBlackBeltTherapeuticsLimitedDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of sales milestone payment payment payable under the license agreemen", "label": "License Agreement, Sales Milestone Payment Payable", "terseLabel": "Sales milestone payable" } } }, "auth_ref": [] }, "casi_LicenseAgreementWithMundipharmaInternationalCorporationLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "LicenseAgreementWithMundipharmaInternationalCorporationLimitedMember", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Mundipharma International Corporation Limited license agreement.", "label": "License Agreement with Mundipharma International Corporation Limited [Member]", "terseLabel": "License Agreement with Mundipharma International Corporation Limited" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://www.entremed.com/role/DisclosureShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r63", "r68", "r1382", "r1385", "r1441", "r1442" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://www.entremed.com/role/DisclosureShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r63", "r68", "r1382", "r1385", "r1441", "r1442" ] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Line Items]", "terseLabel": "Short term borrowings", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r412", "r1382", "r1385", "r1441" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "verboseLabel": "Maximum borrowing", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r63", "r68" ] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://www.entremed.com/role/DisclosureShortTermBorrowingsDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Table]", "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement." } } }, "auth_ref": [ "r63", "r68", "r412", "r1382", "r1385", "r1441" ] }, "casi_LoanToBeAdvanced": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "LoanToBeAdvanced", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails" ], "lang": { "en-us": { "role": { "documentation": "The maximum amount that can be borrowed by the related party borrower under the loans advanced by the company.", "label": "Loan To Be Advanced", "terseLabel": "Loan to be advanced" } } }, "auth_ref": [] }, "casi_LoansAdvancedToRelatedPartyAmountOfEqualInstallments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "LoansAdvancedToRelatedPartyAmountOfEqualInstallments", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of equal installments in which loan will be advanced to related party.", "label": "Loans Advanced To Related Party, Amount Of Equal Installments", "terseLabel": "Convertible loan tranches repaid" } } }, "auth_ref": [] }, "casi_LoansAdvancedToRelatedPartyConversionMinimumEquityFinancingRoundAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "LoansAdvancedToRelatedPartyConversionMinimumEquityFinancingRoundAmount", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueCleaveTherapeuticsIncDetails" ], "lang": { "en-us": { "role": { "documentation": "Minimum amount of equity financing round to be completed by the borrower, to trigger the conversion of loans advanced by the company.", "label": "Loans Advanced To Related Party, Conversion, Minimum Equity Financing Round Amount", "verboseLabel": "Minimum equity financing round amount" } } }, "auth_ref": [] }, "casi_LoansAdvancedToRelatedPartyConversionPercentageOfPerSharePrice": { "xbrltype": "percentItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "LoansAdvancedToRelatedPartyConversionPercentageOfPerSharePrice", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueCleaveTherapeuticsIncDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of per share price at which the loans advanced to related party shall be converted into shares by the company.", "label": "Loans Advanced To Related Party, Conversion, Percentage Of Per Share Price", "verboseLabel": "Percentage of per share price at which the loans advanced will be converted" } } }, "auth_ref": [] }, "casi_LoansAdvancedToRelatedPartyPercentageOfPricePerShareIssuedAtWhichOutstandingPrincipalLoanIsToBeConverted": { "xbrltype": "percentItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "LoansAdvancedToRelatedPartyPercentageOfPricePerShareIssuedAtWhichOutstandingPrincipalLoanIsToBeConverted", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of price per share issued at which outstanding principal loan advanced to related party is to be converted.", "label": "Loans Advanced To Related Party, Percentage Of Price Per Share Issued At Which Outstanding Principal Loan Is To Be Converted", "terseLabel": "Percentage of price per share issued at which the outstanding principal loan is to be converted" } } }, "auth_ref": [] }, "casi_LoansAdvancedToRelatedPartyTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "LoansAdvancedToRelatedPartyTerm", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueCleaveTherapeuticsIncDetails" ], "lang": { "en-us": { "role": { "documentation": "Term of the loan advanced to related party, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Loans Advanced To Related Party, Term", "verboseLabel": "Term of loan provided" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term Debt, Current Maturities", "verboseLabel": "Current portion of long term borrowing", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r194" ] }, "casi_LongTermIncentivePlan2011Member": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "LongTermIncentivePlan2011Member", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to the 2011 Long-Term Incentive Plan.", "label": "Long Term Incentive Plan 2011 [Member]", "terseLabel": "Long Term Incentive Plan 2011" } } }, "auth_ref": [] }, "casi_LongTermIncentivePlan2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "LongTermIncentivePlan2021Member", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to the 2021 Long-Term Incentive Plan.", "label": "Long Term Incentive Plan 2021 [Member]", "terseLabel": "Long Term Incentive Plan 2021" } } }, "auth_ref": [] }, "casi_LongTermIncentivePlan2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "LongTermIncentivePlan2024Member", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2024 long-term incentive plan.", "label": "Long-Term Incentive Plan 2024 [Member]", "terseLabel": "Long Term Incentive Plan 2024" } } }, "auth_ref": [] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermInvestments", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term Investments", "terseLabel": "Long-term investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [ "r187" ] }, "us-gaap_MachineryAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MachineryAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentByTypeDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentByTypeDetails" ], "lang": { "en-us": { "role": { "label": "Machinery and Equipment, Gross", "terseLabel": "Machinery and equipment", "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [ "r106" ] }, "casi_MachineryAndLabEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "MachineryAndLabEquipmentMember", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPpeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information related to machinery and lab equipment.", "label": "Machinery And Lab Equipment [Member]", "terseLabel": "Machinery and lab equipment" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MajorCustomersAxis", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsRisksDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r307", "r1134", "r1136", "r1209", "r1212", "r1546", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MaximumMember", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsCleaveTherapeuticsIncDetails", "http://www.entremed.com/role/DisclosureIntangibleAssetsNarrativesDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails", "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails", "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails", "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPpeDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r151", "r153", "r155", "r156", "r158", "r170", "r172", "r173", "r176", "r177", "r284", "r408", "r409", "r410", "r411", "r493", "r524", "r525", "r526", "r544", "r680", "r786", "r870", "r872", "r880", "r919", "r920", "r987", "r1008", "r1013", "r1014", "r1046", "r1068", "r1069", "r1071", "r1072", "r1087", "r1088", "r1125", "r1133", "r1145", "r1150", "r1152", "r1153", "r1189", "r1190", "r1194", "r1195", "r1210", "r1448", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542" ] }, "casi_MaximumValueOfEntityAssetsFreezed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "MaximumValueOfEntityAssetsFreezed", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsJuventasCellTherapyLtdDetails" ], "lang": { "en-us": { "role": { "documentation": "The maximum value of entity assets freezed.", "label": "Maximum Value of Entity Assets Freezed", "terseLabel": "Entity assets freezed" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r1287" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1287" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Expected volatility", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r524", "r1189", "r1515", "r1516", "r1517" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk Free Interest Rate", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r526", "r1515", "r1516", "r1517" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r522", "r523", "r524", "r525", "r526", "r527", "r678", "r679", "r680", "r1150", "r1152", "r1153", "r1189" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r678", "r679", "r680", "r1150", "r1152", "r1153", "r1189" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MinimumMember", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureIncomeTaxesDetails", "http://www.entremed.com/role/DisclosureIntangibleAssetsNarrativesDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPpeDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r151", "r153", "r155", "r156", "r158", "r170", "r172", "r173", "r176", "r177", "r284", "r408", "r409", "r410", "r411", "r493", "r524", "r525", "r526", "r544", "r680", "r786", "r870", "r872", "r880", "r919", "r920", "r987", "r1008", "r1013", "r1014", "r1046", "r1068", "r1069", "r1071", "r1072", "r1087", "r1088", "r1125", "r1133", "r1145", "r1150", "r1152", "r1153", "r1189", "r1190", "r1194", "r1210", "r1448", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MinorityInterest", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsJuventasCellTherapyLtdDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Equity attributable to noncontrolling interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r78", "r130", "r233", "r235", "r236", "r347", "r413", "r415", "r416", "r417", "r420", "r421", "r846", "r932", "r1526" ] }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MinorityInterestDecreaseFromRedemptions", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingChangesInRedeemableNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "negatedLabel": "Redemption of Wuxi NCI", "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests)." } } }, "auth_ref": [ "r52", "r116", "r124" ] }, "us-gaap_MinorityInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MinorityInterestLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Line Items]", "terseLabel": "Noncontrolling Interest", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MinorityInterestTable", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Table]", "documentation": "Disclosure of information about noncontrolling interest, including, but not limited to, name of subsidiary, ownership percentage held by parent, ownership percentage held by noncontrolling owner, amount of noncontrolling interest and its location in statement of financial position, explanation of increase (decrease) in noncontrolling interest, noncontrolling interest share of net income (loss) of subsidiary and its location in statement of income, amount of noncontrolling interest represented by preferred stock, description and dividend requirement of preferred stock, and nature of noncontrolling interest." } } }, "auth_ref": [ "r50", "r54", "r78", "r87" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r1307" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r1315" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsRisksDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r307", "r1134", "r1136", "r1209", "r1212", "r1546", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r1288" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities", "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit." } } }, "auth_ref": [ "r228" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets." } } }, "auth_ref": [ "r228" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Net cash provided by (used in) operating activities", "totalLabel": "Net cash used in operating activities", "verboseLabel": "Cash outflow for operating activities", "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity." } } }, "auth_ref": [ "r100", "r101", "r102" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareComputationDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to CASI Pharmaceuticals, Inc.", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r91", "r102", "r134", "r180", "r182", "r206", "r208", "r213", "r233", "r235", "r236", "r241", "r248", "r252", "r253", "r254", "r255", "r256", "r259", "r260", "r266", "r347", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r440", "r443", "r446", "r450", "r533", "r589", "r645", "r674", "r702", "r855", "r949", "r972", "r973", "r1106", "r1108", "r1110", "r1223", "r1444" ] }, "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingChangesInRedeemableNoncontrollingInterestDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest", "terseLabel": "Less:Loss attributable to redeemable noncontrolling interest", "verboseLabel": "Share of CASI Wuxi net loss", "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest." } } }, "auth_ref": [ "r87" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareComputationDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "New Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "casi_NonFinancialAssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "NonFinancialAssetsFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of non-financial assets measured at fair value.", "label": "Non-Financial Assets, Fair Value Disclosure", "terseLabel": "Non-financial assets, measured at fair value" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r1287" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r1250", "r1261", "r1271", "r1295", "r1304" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r1278" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r1277" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r1295" ] }, "casi_NonRoyaltyExclusiveDistributionAdditionalPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "NonRoyaltyExclusiveDistributionAdditionalPeriod", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsChinaResourcesPharmaceuticalCommercialGroupInternationalTradingCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsGuangzhouGloriaBiosciencesCoLtdDetails" ], "lang": { "en-us": { "role": { "documentation": "The additional period after the product launch, for which the company has non-royalty exclusive distribution rights, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Non Royalty Exclusive Distribution Additional Period", "terseLabel": "Non royalty exclusive distribution additional period (in years)", "verboseLabel": "Agreement extension" } } }, "auth_ref": [] }, "casi_NonRoyaltyExclusiveDistributionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "NonRoyaltyExclusiveDistributionPeriod", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsChinaResourcesPharmaceuticalCommercialGroupInternationalTradingCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsGuangzhouGloriaBiosciencesCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPharmathenGlobalBvDetails" ], "lang": { "en-us": { "role": { "documentation": "The period after the product launch, for which the company has non-royalty exclusive distribution rights, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Non Royalty Exclusive Distribution Period", "terseLabel": "Non royalty exclusive distribution period (in years)" } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r1315" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r1315" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "verboseLabel": "Non-cash investing and financing activities:" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Non-operating (expense) income:" } } }, "auth_ref": [] }, "casi_NumberMilestonesAchieved": { "xbrltype": "integerItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "NumberMilestonesAchieved", "presentation": [ "http://www.entremed.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of milestones achieved.", "label": "Number Milestones Achieved", "terseLabel": "Number of milestones achieved" } } }, "auth_ref": [] }, "casi_NumberMilestonesPaymentsOutstanding": { "xbrltype": "integerItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "NumberMilestonesPaymentsOutstanding", "presentation": [ "http://www.entremed.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of milestone payments yet to be paid.", "label": "Number Milestones Payments Outstanding", "terseLabel": "Number of milestone payments yet to be paid" } } }, "auth_ref": [] }, "casi_NumberOfGuaranteeAgreements": { "xbrltype": "integerItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "NumberOfGuaranteeAgreements", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of guarantee agreements.", "label": "Number of Guarantee Agreements", "terseLabel": "Number of guarantee agreements" } } }, "auth_ref": [] }, "casi_NumberOfInstallmentsForUpfrontPayment": { "xbrltype": "integerItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "NumberOfInstallmentsForUpfrontPayment", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPrecisionAutoimmuneTherapeuticsCoLtdDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of installments for upfront payment.", "label": "Number Of Installments For Upfront Payment", "terseLabel": "Number of installments for upfront payment" } } }, "auth_ref": [] }, "casi_NumberOfInvestors": { "xbrltype": "integerItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "NumberOfInvestors", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of investors.", "label": "Number Of Investors", "terseLabel": "Number of investors" } } }, "auth_ref": [] }, "casi_NumberOfMajorSuppliers": { "xbrltype": "integerItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "NumberOfMajorSuppliers", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsRisksDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of major suppliers, where each supplier accounting over 10% of supplies.", "label": "Number Of Major Suppliers", "terseLabel": "Number of major suppliers" } } }, "auth_ref": [] }, "casi_NumberOfNewWarrantsSubscribed": { "xbrltype": "sharesItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "NumberOfNewWarrantsSubscribed", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants to be subscribed by the company.", "label": "Number Of New Warrants Subscribed", "terseLabel": "Number of new warrants subscribed (in shares)" } } }, "auth_ref": [] }, "casi_NumberOfOperatingLeases": { "xbrltype": "integerItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "NumberOfOperatingLeases", "presentation": [ "http://www.entremed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of operating leases.", "label": "Number of Operating Leases", "terseLabel": "Number of operating lease" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentReportingDetails" ], "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "verboseLabel": "Number of reportable segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r1118", "r1124", "r1403" ] }, "casi_NumberOfSharesToBeSubscribed": { "xbrltype": "sharesItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "NumberOfSharesToBeSubscribed", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares subscribed by the company.", "label": "Number Of Shares To Be Subscribed", "terseLabel": "Number of shares subscribed (in shares)" } } }, "auth_ref": [] }, "casi_NumberOfWarrantsSubscribedPerShare": { "xbrltype": "pureItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "NumberOfWarrantsSubscribedPerShare", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number Of Warrants Subscribed Per Share Ratio.", "label": "Number Of Warrants Subscribed Per Share", "terseLabel": "Number of shares subscribed per warrant (in shares)" } } }, "auth_ref": [] }, "casi_NumberOfWhollyOwnedSubsidiaries": { "xbrltype": "integerItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "NumberOfWhollyOwnedSubsidiaries", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of wholly owned subsidaries.", "label": "Number of Wholly Owned Subsidiaries", "terseLabel": "Number of wholly owned subsidiaries" } } }, "auth_ref": [] }, "casi_OfficeSpaceLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "OfficeSpaceLeaseMember", "presentation": [ "http://www.entremed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to office space lease.", "label": "Office Space Lease", "terseLabel": "Office Space Lease" } } }, "auth_ref": [] }, "casi_OpenMarketSaleAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "OpenMarketSaleAgreementMember", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Information related to Open Market Sale Agreement.", "label": "Open Market Sale Agreement [Member]", "terseLabel": "Open Market Sale Agreement" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r137", "r1106", "r1110", "r1117", "r1397", "r1404", "r1405", "r1406", "r1407" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Rent expenses", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r731", "r1198" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureLeasesFutureUndiscountedCashFlowsDetailsCalc2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 }, "http://www.entremed.com/role/DisclosureLeasesRightOfUseAssetsAndLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.entremed.com/role/DisclosureLeasesFutureUndiscountedCashFlowsDetails", "http://www.entremed.com/role/DisclosureLeasesRightOfUseAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "totalLabel": "Total lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r727" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureLeasesRightOfUseAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails", "http://www.entremed.com/role/DisclosureLeasesFutureUndiscountedCashFlowsDetails", "http://www.entremed.com/role/DisclosureLeasesRightOfUseAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "netLabel": "Lease liabilities, current", "terseLabel": "Lease liabilities-current (Note 5)", "verboseLabel": "Amounts due within 12 months", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r727" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails", "http://www.entremed.com/role/DisclosureLeasesRightOfUseAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r728" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 }, "http://www.entremed.com/role/DisclosureLeasesRightOfUseAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails", "http://www.entremed.com/role/DisclosureLeasesFutureUndiscountedCashFlowsDetails", "http://www.entremed.com/role/DisclosureLeasesRightOfUseAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liabilities-noncurrent (Note 5)", "verboseLabel": "Non-current lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r727" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails", "http://www.entremed.com/role/DisclosureLeasesRightOfUseAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": [ "r728" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureLeasesSupplementalCashFlowDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "verboseLabel": "Operating cash flows", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r729", "r733" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureLeasesRightOfUseAssetsAndLiabilitiesDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Right of use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r726" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.entremed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "verboseLabel": "Weighted average discount rates", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r736", "r1198" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.entremed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "verboseLabel": "Weighted average remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r735", "r1198" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r575" ] }, "us-gaap_OptionIndexedToIssuersEquityTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OptionIndexedToIssuersEquityTypeAxis", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity, Type [Axis]", "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock." } } }, "auth_ref": [ "r56", "r57", "r125" ] }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OptionIndexedToIssuersEquityTypeDomain", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity, Type [Domain]", "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "DESCRIPTION OF BUSINESS" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "verboseLabel": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r191" ] }, "us-gaap_OtherCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherCommitmentsLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Line Items]", "terseLabel": "COMMITMENTS AND CONTINGENCIES", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherCommitmentsTable", "presentation": [ "http://www.entremed.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Table]", "documentation": "Disclosure of information about obligations resulting from other commitments." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "verboseLabel": "Foreign currency translation adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r9", "r15", "r123" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Gain (Loss) Arising During Period, Tax", "negatedLabel": "Foreign currency translation adjustment", "documentation": "Amount of tax expense (benefit), before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r4", "r5", "r708", "r711", "r718" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax", "negatedLabel": "Available for sale debt security reclassification adjustment", "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities." } } }, "auth_ref": [ "r8", "r83", "r205", "r341" ] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax", "verboseLabel": "Fair value change of available for sale debt security", "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r203", "r204", "r341" ] }, "us-gaap_OtherCostAndExpenseOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherCostAndExpenseOperating", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Other Cost and Expense, Operating", "terseLabel": "Other operating expenses", "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation." } } }, "auth_ref": [ "r92", "r867", "r1121" ] }, "us-gaap_OtherEmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherEmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other Employee-related Liabilities, Current", "terseLabel": "Payroll and welfare payable", "documentation": "Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r65" ] }, "us-gaap_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherIncome", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureGrantsDetails" ], "lang": { "en-us": { "role": { "label": "Other Income", "terseLabel": "Other income", "documentation": "Amount of revenue and income classified as other." } } }, "auth_ref": [ "r866", "r951", "r1053", "r1054", "r1055", "r1213", "r1214" ] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsNarrativesDetails", "http://www.entremed.com/role/DisclosureIntangibleAssetsNetDefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Other Liabilities [Member]", "terseLabel": "Others", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [ "r1094", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1429", "r1431", "r1432", "r1433" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Others", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r65", "r1199" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 }, "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails", "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "totalLabel": "Other Liabilities", "verboseLabel": "Other liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r70" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income", "verboseLabel": "Other non-operating income (expenses)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r94", "r1183" ] }, "us-gaap_OtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherOperatingIncome", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Operating Income", "terseLabel": "Other operating income", "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation." } } }, "auth_ref": [ "r84" ] }, "us-gaap_OtherOperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherOperatingIncomeExpenseMember", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPharmathenGlobalBvDetails" ], "lang": { "en-us": { "role": { "label": "Other Operating Income (Expense) [Member]", "terseLabel": "Other income", "verboseLabel": "Other operating income", "documentation": "Primary financial statement caption encompassing other operating income (expense)." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r1287" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1248", "r1259", "r1269", "r1302" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r1251", "r1262", "r1272", "r1305" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1251", "r1262", "r1272", "r1305" ] }, "casi_OwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "OwnershipPercentage", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails", "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee.", "label": "Ownership Percentage", "terseLabel": "Equity ownership (as a percent)" } } }, "auth_ref": [] }, "casi_PanaceaVentureHealthcareFundIiLpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "PanaceaVentureHealthcareFundIiLpMember", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsPurchaseOfOrdinarySharesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Panacea Venture Healthcare Fund II, L.P.", "label": "Panacea Venture Healthcare Fund II LP [Member]", "terseLabel": "Panacea Venture Healthcare Fund II, L.P." } } }, "auth_ref": [] }, "srt_ParentCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ParentCompanyMember", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Parent Company [Member]", "terseLabel": "Parent Company", "documentation": "Registrant with controlling financial interest in one or more subsidiaries. Controlling interest in subsidiary includes, but is not limited to, primary beneficiary of variable interest entity (VIE). Controlling interest in subsidiary excludes broker-dealer with controlling financial interest in subsidiary but control is likely to be temporary." } } }, "auth_ref": [ "r150", "r234", "r244", "r835" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r1276" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "ACCRUED AND OTHER CURRENT LIABILITIES, AND OTHER LIABILITIES" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase of ordinary shares", "negatedTerseLabel": "Repurchase of ordinary share", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r99" ] }, "casi_PaymentsForUnderwriterSSalesCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "PaymentsForUnderwriterSSalesCommissions", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred as sales commission associated with underwriting activities.", "label": "Payments For Underwriter's Sales Commissions", "terseLabel": "Underwriter's sales commission" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDividendsMinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsOfDividendsMinorityInterest", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Ordinary Dividends, Noncontrolling Interest", "negatedLabel": "Dividend payment to Wuxi LP", "documentation": "Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests." } } }, "auth_ref": [ "r99" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of issuance costs", "negatedTerseLabel": "Payment of share issuance costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r28" ] }, "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Additional Interest in Subsidiaries", "negatedLabel": "Investment in subsidiaries", "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period." } } }, "auth_ref": [ "r26" ] }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsToAcquireEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Equity Method Investments", "negatedLabel": "Cash paid to acquire equity interests in an equity method investee", "terseLabel": "Payments to acquire equity investments", "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence." } } }, "auth_ref": [ "r26" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Purchase of intangible assets", "negatedTerseLabel": "Purchases of intangible asset", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r98" ] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Investments", "terseLabel": "Payments to acquire investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r97" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, plant and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r98" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r1286" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r1286" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r1278" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r1295" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r1288" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r1277" ] }, "casi_PercentageOfEquityHeldInJointVenture": { "xbrltype": "percentItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "PercentageOfEquityHeldInJointVenture", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of equity held in joint venture.", "label": "Percentage of Equity Held in Joint Venture", "terseLabel": "Percentage of equity held in joint venture" } } }, "auth_ref": [] }, "casi_PercentageOfInterestInBoardSeats": { "xbrltype": "percentItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "PercentageOfInterestInBoardSeats", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents percentage of interest in board seats.", "label": "Percentage of Interest in Board Seats", "terseLabel": "Percentage of interest in board seats" } } }, "auth_ref": [] }, "casi_PercentageOfNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "PercentageOfNetSales", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of net sales.", "label": "Percentage of Net Sales", "terseLabel": "Percentage of net sales" } } }, "auth_ref": [] }, "casi_PercentageOfValuationAllowanceRecognized": { "xbrltype": "percentItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "PercentageOfValuationAllowanceRecognized", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of valuation allowance recognized.", "label": "Percentage of Valuation Allowance Recognized", "terseLabel": "Percentage of valuation allowance recognized" } } }, "auth_ref": [] }, "casi_PerformanceBasedOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "PerformanceBasedOptionMember", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails", "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to performance-based options.", "label": "Performance Based Option [Member]", "terseLabel": "Performance Based Option" } } }, "auth_ref": [] }, "casi_PharmathenGlobalBvMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "PharmathenGlobalBvMember", "presentation": [ "http://www.entremed.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPharmathenGlobalBvDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to Pharmathen Global BV.", "label": "Pharmathen Global Bv [Member]", "terseLabel": "Pharmathen Global BV" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PlanNameAxis", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PlanNameDomain", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r1279" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r1335" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r1278" ] }, "casi_PotentialMilestonePaymentAndRoyalty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "PotentialMilestonePaymentAndRoyalty", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBlackBeltTherapeuticsLimitedDetails" ], "lang": { "en-us": { "role": { "documentation": "The potential milestone and royalty payment.", "label": "Potential Milestone Payment And Royalty", "terseLabel": "Potential milestones and royalties" } } }, "auth_ref": [] }, "casi_PrecisionAutoimmuneTherapeuticsCo.LtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "PrecisionAutoimmuneTherapeuticsCo.LtdMember", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPrecisionAutoimmuneTherapeuticsCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the Precision Autoimmune Therapeutics Co., Ltd., (\"PAT\").", "label": "Precision Autoimmune Therapeutics Co. Ltd [Member]", "terseLabel": "Precision Autoimmune Therapeutics Co., Ltd" } } }, "auth_ref": [] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockMember", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsSummaryOfLongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r1215", "r1216", "r1219", "r1220", "r1221", "r1222", "r1575", "r1585" ] }, "casi_PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "PrefundedWarrantsMember", "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShareDetails", "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to pre-funded warrants.", "label": "Prefunded Warrants [Member]", "terseLabel": "Prefunded warrants" } } }, "auth_ref": [] }, "casi_PremiumPercentageOverAverageClosingPrice": { "xbrltype": "percentItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "PremiumPercentageOverAverageClosingPrice", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of premium to the average closing price.", "label": "Premium Percentage Over Average Closing Price", "terseLabel": "Premium percentage over average closing price" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "verboseLabel": "Prepaid expenses and other", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1362" ] }, "us-gaap_ProceedsFromCollectionOfOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromCollectionOfOtherReceivables", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Collection of Other Receivables", "terseLabel": "Other receivables", "documentation": "Amount of cash inflow from the collection of receivables classified as other." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from issuance of convertible note", "verboseLabel": "Proceeds from issuance of convertible notes", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r27" ] }, "casi_ProceedsFromExtinguishmentOfInvestmentInConvertibleLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ProceedsFromExtinguishmentOfInvestmentInConvertibleLoan", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of proceeds from extinguishment of investment in a convertible loan.", "label": "Proceeds from Extinguishment of Investment in a Convertible Loan", "terseLabel": "Proceeds from extinguishment of investment in a convertible loan" } } }, "auth_ref": [] }, "casi_ProceedsFromGovernmentGrant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ProceedsFromGovernmentGrant", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureGrantsDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to government grant received from Jiangsu Province Wuxi Huishan Economic Development Zone for development project.", "label": "Proceeds from Government Grant", "terseLabel": "Government grant received", "verboseLabel": "Receipt from government for return of Wuxi land use right" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsPurchaseOfOrdinarySharesDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Gross proceeds from the offering", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r7" ] }, "casi_ProceedsFromIssuanceOfCommonStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity through the issuance of common stock and warrants.", "label": "Proceeds from Issuance of Common Stock and Warrants", "terseLabel": "Proceeds from issuance of ordinary share", "verboseLabel": "Proceeds from issuance of ordinary shares" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Lines of Credit", "terseLabel": "Proceeds from bank borrowings", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r27", "r1382", "r1385" ] }, "casi_ProceedsFromReimbursementOfLaborPreclinicalAndClinalExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ProceedsFromReimbursementOfLaborPreclinicalAndClinalExpense", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from certain labor cost and certain preclinical and clinical services", "label": "Proceeds from Reimbursement Of Labor, Preclinical And Clinal Expense", "terseLabel": "Reimbursement of labor, preclinical and clinal expense" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Equity Securities, FV-NI", "verboseLabel": "Proceeds from sales of equity securities", "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity." } } }, "auth_ref": [ "r139", "r226" ] }, "us-gaap_ProceedsFromSaleOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromSaleOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Intangible Assets", "terseLabel": "Proceeds from sale of intangible assets", "verboseLabel": "Proceeds from sale of intangible assets", "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r96" ] }, "casi_ProceedsFromSalesOrMaturityOfShortTermInvestmentsAndTermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ProceedsFromSalesOrMaturityOfShortTermInvestmentsAndTermDeposits", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of cash inflow associated with proceeds from sales or maturity of short term investments and term deposits.", "label": "Proceeds from Sales or Maturity of Short Term Investments and Term Deposits", "terseLabel": "Proceeds from sales or maturity of short term investments and term deposits" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfCashFlowsDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "verboseLabel": "Proceeds from exercise of share options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r7", "r19" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net loss", "verboseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r180", "r182", "r206", "r208", "r227", "r233", "r235", "r236", "r241", "r248", "r256", "r259", "r260", "r347", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r440", "r533", "r589", "r645", "r647", "r650", "r651", "r674", "r702", "r831", "r833", "r854", "r899", "r949", "r972", "r973", "r1181", "r1182", "r1224", "r1374", "r1444" ] }, "casi_ProfitSharingLiabilityNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ProfitSharingLiabilityNonCurrent", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of noncurrent portion of Profit-sharing liability.", "label": "Profit-sharing Liability Non current", "terseLabel": "Profit-sharing liability to Juventas" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "PROPERTY, PLANT AND EQUIPMENT" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPpeDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r14", "r738" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosurePropertyPlantAndEquipment" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY, PLANT AND EQUIPMENT", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r105", "r144", "r145", "r146" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentByTypeDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentByTypeDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property, plant and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r106", "r188", "r851" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPpeDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r738" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentByTypeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentByTypeDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r14", "r738", "r836", "r851", "r1199" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r14", "r144", "r145", "r849" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property, plant and equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r14" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPpeDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r106", "r738" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPpeDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "casi_ProposedPurchasePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ProposedPurchasePricePerShare", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Per share amount proposed to be purchase.", "label": "Proposed Purchase Price Per Share", "terseLabel": "Proposed purchase price per share" } } }, "auth_ref": [] }, "casi_ProvisionForExcessLossInSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ProvisionForExcessLossInSubsidiaries", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of provision for excess loss in subsidiaries.", "label": "Provision For Excess Loss In Subsidiaries", "terseLabel": "Provision of excess loss in subsidiaries" } } }, "auth_ref": [] }, "casi_PurchaseOfShortTermInvestmentsAndTermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "PurchaseOfShortTermInvestmentsAndTermDeposits", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of cash outflow associated with purchase of short term investments and term deposits.", "label": "Purchase of Short Term Investments and Term Deposits", "negatedLabel": "Purchase of short term investments and term deposits" } } }, "auth_ref": [] }, "us-gaap_PutOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PutOptionMember", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "label": "Put Option [Member]", "terseLabel": "Put option", "documentation": "A financial contract between two parties, the buyer and the seller (writer) of the option, where the buyer has the right but not the obligation to sell a commodity or financial instrument (the underlying instrument) to the seller (writer) at a certain time for a certain price (the strike price). The seller (writer) has the obligation to purchase the underlying asset at that strike price, if the buyer exercises the option." } } }, "auth_ref": [ "r1035", "r1036" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r1276" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r1276" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeAxis", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsCleaveTherapeuticsIncDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureIncomeTaxesDetails", "http://www.entremed.com/role/DisclosureIntangibleAssetsNarrativesDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails", "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails", "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPpeDetails" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r151", "r153", "r155", "r156", "r158", "r170", "r172", "r173", "r176", "r177", "r284", "r408", "r409", "r410", "r411", "r478", "r493", "r524", "r525", "r526", "r532", "r544", "r680", "r760", "r769", "r786", "r870", "r872", "r880", "r919", "r920", "r987", "r1008", "r1013", "r1014", "r1046", "r1068", "r1069", "r1071", "r1072", "r1087", "r1088", "r1125", "r1133", "r1145", "r1150", "r1152", "r1153", "r1189", "r1190", "r1194", "r1195", "r1210", "r1217", "r1439", "r1448", "r1516", "r1538", "r1539", "r1540", "r1541", "r1542" ] }, "casi_RangeFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "RangeFiveMember", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationStockOptionOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Range Five [Member]", "terseLabel": "$42.70" } } }, "auth_ref": [] }, "casi_RangeFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "RangeFourMember", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationStockOptionOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Range Four [Member]", "terseLabel": "$5.78 - $6.89" } } }, "auth_ref": [] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeMember", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsCleaveTherapeuticsIncDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureIncomeTaxesDetails", "http://www.entremed.com/role/DisclosureIntangibleAssetsNarrativesDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails", "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails", "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPpeDetails" ], "lang": { "en-us": { "role": { "label": "Range [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r151", "r153", "r155", "r156", "r158", "r170", "r172", "r173", "r176", "r177", "r284", "r408", "r409", "r410", "r411", "r478", "r493", "r524", "r525", "r526", "r532", "r544", "r680", "r760", "r769", "r786", "r870", "r872", "r880", "r919", "r920", "r987", "r1008", "r1013", "r1014", "r1046", "r1068", "r1069", "r1071", "r1072", "r1087", "r1088", "r1125", "r1133", "r1145", "r1150", "r1152", "r1153", "r1189", "r1190", "r1194", "r1195", "r1210", "r1217", "r1439", "r1448", "r1516", "r1538", "r1539", "r1540", "r1541", "r1542" ] }, "casi_RangeOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "RangeOneMember", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationStockOptionOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Range One [Member]", "terseLabel": "$1.26 - $1.93" } } }, "auth_ref": [] }, "casi_RangeThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "RangeThreeMember", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationStockOptionOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Range Three [Member]", "terseLabel": "$3.59 - $5.20" } } }, "auth_ref": [] }, "casi_RangeTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "RangeTwoMember", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationStockOptionOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Range Two [Member]", "terseLabel": "$2.31 - $2.69" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r1243", "r1254", "r1264", "r1297" ] }, "casi_RedeemableNonControllingInterestAndLongTermBorrowingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "RedeemableNonControllingInterestAndLongTermBorrowingAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "REDEEMABLE NONCONTROLLING INTEREST AND A LONG TERM BORROWING" } } }, "auth_ref": [] }, "casi_RedeemableNonControllingInterestAndLongTermBorrowingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "RedeemableNonControllingInterestAndLongTermBorrowingTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowing" ], "lang": { "en-us": { "role": { "documentation": "Entire disclosure of redeemable non controlling interest and long term borrowing.", "label": "Redeemable Non controlling Interest and Long Term Borrowing [Text Block]", "terseLabel": "REDEEMABLE NONCONTROLLING INTEREST AND A LONG TERM BORROWING" } } }, "auth_ref": [] }, "casi_RedeemableNoncontrollingInterestAccretionToRedemptionValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "RedeemableNoncontrollingInterestAccretionToRedemptionValueAdjustment", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "documentation": "Amount of decrease to net income for accretion of redeemable noncontrolling interest to its redemption value to derive net income apportioned to common stockholders.", "label": "Redeemable Noncontrolling Interest, Accretion To Redemption Value, Adjustment", "terseLabel": "Accretion to redeemable noncontrolling interest redemption value" } } }, "auth_ref": [] }, "us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RedeemableNoncontrollingInterestEquityCommonCarryingAmount", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingChangesInRedeemableNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "label": "Redeemable Noncontrolling Interest, Equity, Common, Carrying Amount", "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at beginning of year", "documentation": "As of the reporting date, the carrying amount of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of common shares (regardless of class), limited partnership units (regardless of class), non-preferential membership interests, or any other form of common equity regardless of investee entity legal form." } } }, "auth_ref": [ "r1449", "r1451", "r1452" ] }, "casi_RedeemableNoncontrollingInterestEquityCommonForeignCurrencyTranslationAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "RedeemableNoncontrollingInterestEquityCommonForeignCurrencyTranslationAdjustments", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingChangesInRedeemableNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "documentation": "Adjustments to noncontrolling interests which are redeemable by the (parent) entity foreign currency translation adjustments.", "label": "Redeemable Noncontrolling Interest, Equity, Common, Foreign Currency Translation Adjustments", "terseLabel": "Foreign currency translation adjustment" } } }, "auth_ref": [] }, "us-gaap_RedeemableNoncontrollingInterestTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RedeemableNoncontrollingInterestTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingTables" ], "lang": { "en-us": { "role": { "label": "Redeemable Noncontrolling Interest [Table Text Block]", "terseLabel": "Schedule of changes in redeemable noncontrolling interest", "documentation": "Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity." } } }, "auth_ref": [ "r443", "r1451", "r1452" ] }, "casi_ReductionInCarryingAmountOfRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ReductionInCarryingAmountOfRightOfUseAssets", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "This represents reduction in the carrying amount of the right-of-use assets.", "label": "Reduction in the Carrying Amount of the Right-of-Use Assets", "terseLabel": "Reduction in the carrying amount of the right-of-use assets" } } }, "auth_ref": [] }, "casi_ReductionInRegisteredCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ReductionInRegisteredCapital", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of reduction in registered capital.", "label": "Reduction in Registered Capital", "terseLabel": "Reduction in capital" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyDomain", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails", "http://www.entremed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r233", "r240", "r241", "r308", "r485", "r490", "r745", "r746", "r841", "r848", "r922", "r923", "r924", "r926", "r927", "r947", "r981", "r1584" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyMember", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.entremed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "terseLabel": "Related Party", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r233", "r240", "r241", "r745", "r746", "r747", "r748", "r841", "r848", "r922", "r923", "r924", "r926", "r927", "r947", "r981" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r233", "r240", "r241", "r745", "r746", "r1534" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [ "r233", "r240", "r241", "r1534" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsPurchaseOfOrdinarySharesDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "terseLabel": "RELATED PARTY TRANSACTIONS", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r233", "r240", "r241", "r308", "r745", "r746", "r748", "r954", "r955", "r958" ] }, "us-gaap_RelatedPartyTransactionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionRate", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueCleaveTherapeuticsIncDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction, Rate", "terseLabel": "Interest rate (as a percent)", "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties." } } }, "auth_ref": [ "r1532" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails", "http://www.entremed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r233", "r240", "r241", "r308", "r485", "r490", "r745", "r746", "r841", "r848", "r922", "r923", "r924", "r926", "r927", "r947", "r981", "r1534", "r1584" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "RELATED PARTY TRANSACTIONS", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r742", "r743", "r744", "r746", "r749", "r896", "r897", "r898", "r956", "r957", "r958", "r978", "r980" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.entremed.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBlackBeltTherapeuticsLimitedDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsChinaResourcesPharmaceuticalCommercialGroupInternationalTradingCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsCleaveTherapeuticsIncDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsGuangzhouGloriaBiosciencesCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsJuventasCellTherapyLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPharmathenGlobalBvDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsBioinventInternationalAbSummaryOfInvestmentsDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueCleaveTherapeuticsIncDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsSummaryOfLongTermInvestmentsDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsPurchaseOfOrdinarySharesDetails", "http://www.entremed.com/role/DisclosureSubsequentEventsDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r174", "r175", "r233", "r242", "r243", "r425", "r454", "r748", "r770", "r839", "r1101", "r1102", "r1103", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1506", "r1507", "r1508", "r1509" ] }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBlackBeltTherapeuticsLimitedDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off", "terseLabel": "In-process research and development expensed", "documentation": "Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both." } } }, "auth_ref": [ "r219", "r388", "r1090", "r1489" ] }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBlackBeltTherapeuticsLimitedDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Asset Acquired Other than through Business Combination, Writeoff, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both." } } }, "auth_ref": [ "r388", "r1090" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense.", "negatedLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r546", "r1090", "r1106", "r1107", "r1121", "r1543" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r545" ] }, "casi_ResearchAndDevelopmentInProcess1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ResearchAndDevelopmentInProcess1", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsCleaveTherapeuticsIncDetails" ], "lang": { "en-us": { "role": { "documentation": "The amounts of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research And Development In Process 1", "verboseLabel": "Acquired in-process research and development" } } }, "auth_ref": [] }, "us-gaap_ResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchMember", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Research Tax Credit Carryforward [Member]", "terseLabel": "Research Tax Credit Carryforward", "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes." } } }, "auth_ref": [ "r1495" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r1244", "r1255", "r1265", "r1298" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r1245", "r1256", "r1266", "r1299" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r1252", "r1263", "r1273", "r1306" ] }, "us-gaap_RestrictedInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestrictedInvestments", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureRestrictedNetAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Investments", "terseLabel": "Restricted net assets", "documentation": "Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet." } } }, "auth_ref": [ "r1073", "r1074" ] }, "casi_RestrictedNetAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "RestrictedNetAssetsAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "RESTRICTED NET ASSETS" } } }, "auth_ref": [] }, "casi_RestrictedNetAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "RestrictedNetAssetsTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureRestrictedNetAssets" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restricted net assets.", "label": "Restricted Net Assets [Text Block]", "terseLabel": "RESTRICTED NET ASSETS" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r76", "r116", "r845", "r877", "r879", "r894", "r931", "r1199" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RetainedEarningsMember", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "verboseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r178", "r179", "r180", "r245", "r246", "r247", "r249", "r256", "r258", "r260", "r348", "r349", "r400", "r439", "r533", "r577", "r578", "r586", "r587", "r588", "r590", "r644", "r645", "r660", "r662", "r663", "r665", "r672", "r723", "r725", "r874", "r876", "r900", "r1585" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r148", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r1091" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedStatementsOfOperationsAndComprehensiveLossDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Revenues", "terseLabel": "Revenues", "verboseLabel": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r135", "r136", "r214", "r233", "r235", "r236", "r275", "r286", "r287", "r300", "r302", "r304", "r305", "r307", "r347", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r702", "r831", "r833", "r1121", "r1183", "r1213", "r1214", "r1444" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureLeasesSupplementalCashFlowDetails" ], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "verboseLabel": "Right of use assets obtained in exchange for lease obligations", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r734", "r1198" ] }, "casi_RightOfUseAssetsRemeasured": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "RightOfUseAssetsRemeasured", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureLeasesSupplementalCashFlowDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount right of use assets remeasured.", "label": "Right of Use Assets Remeasured", "terseLabel": "Increase of right of use assets from remeasurement" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r1315" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r1315" ] }, "casi_SaleOfStockMaximumAggregateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "SaleOfStockMaximumAggregateOfferingPrice", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum aggregate offering price of stock agreed to be sold in a stock sale transaction.", "label": "Sale Of Stock, Maximum Aggregate Offering Price", "terseLabel": "Offer or sale of Aggregate price" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShareDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsPurchaseOfOrdinarySharesDetails", "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of ordinary shares sold (in shares)", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "casi_SalesAndMarketingServicesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "SalesAndMarketingServicesPayableCurrent", "crdr": "credit", "calculation": { "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of current portion of sales and marketing services payable as at the end of the reporting period.", "label": "Sales and Marketing Services Payable, Current", "terseLabel": "Payable to sales and marketing services" } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsRisksDetails" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "terseLabel": "Revenues", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r307", "r1399", "r1400" ] }, "casi_ScheduleOfAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ScheduleOfAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesAndOtherLiabilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of accrued and other current liabilities and other liabilities.", "label": "Schedule of Accrued and Other Current Liabilities and Other Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued and other current liabilities and other liabilities" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r270" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfCashAndCashEquivalentsTable", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Cash and Cash Equivalents [Table]", "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent." } } }, "auth_ref": [] }, "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantTables" ], "lang": { "en-us": { "role": { "label": "Condensed Balance Sheet [Table Text Block]", "terseLabel": "Schedule of Condensed Balance Sheets", "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r1352", "r1383", "r1390", "r1544" ] }, "srt_ScheduleOfCondensedCashFlowStatementTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScheduleOfCondensedCashFlowStatementTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantTables" ], "lang": { "en-us": { "role": { "label": "Condensed Cash Flow Statement [Table Text Block]", "terseLabel": "Schedule of Condensed Statements of Cash Flows", "documentation": "Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r1352", "r1383", "r1390", "r1544" ] }, "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantTables" ], "lang": { "en-us": { "role": { "label": "Condensed Income Statement [Table Text Block]", "terseLabel": "Schedule of Condensed Statements of Operations and Comprehensive Loss", "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r1352", "r1383", "r1390", "r1544" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of deferred income tax assets and liabilities", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r1493" ] }, "casi_ScheduleOfDescriptionOfBusinessAndBasisOfPresentationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ScheduleOfDescriptionOfBusinessAndBasisOfPresentationTable", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBlackBeltTherapeuticsLimitedDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsChinaResourcesPharmaceuticalCommercialGroupInternationalTradingCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsCleaveTherapeuticsIncDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsGuangzhouGloriaBiosciencesCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsJuventasCellTherapyLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPharmathenGlobalBvDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPrecisionAutoimmuneTherapeuticsCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Schedule of Description of Business and Basis of Presentation [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net loss per share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1396" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of reconciliation of provision for income taxes to the federal statutory rate", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r555", "r1149", "r1490" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Schedule of compensation expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r49" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPrecisionAutoimmuneTherapeuticsCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r344", "r345", "r346", "r585", "r702", "r1339", "r1340", "r1341", "r1497", "r1498", "r1499", "r1500" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of financial assets and liabilities accounted for at fair value on a recurring basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1513", "r1514" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsNarrativesDetails", "http://www.entremed.com/role/DisclosureIntangibleAssetsNetDefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r382", "r390", "r393", "r394", "r398", "r789", "r1090", "r1094", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of changes in intangible assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r1094", "r1428" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of domestic and foreign loss before income taxes", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r1382", "r1388" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureInventoriesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r13", "r80", "r81", "r82" ] }, "us-gaap_ScheduleOfInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfInvestmentsLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsBioinventInternationalAbSummaryOfInvestmentsDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueCleaveTherapeuticsIncDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Investments [Line Items]", "terseLabel": "Schedule of Investments", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1005", "r1007", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061" ] }, "us-gaap_ScheduleOfInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfInvestmentsTable", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsBioinventInternationalAbSummaryOfInvestmentsDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueCleaveTherapeuticsIncDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Investments [Table]", "documentation": "Disclosure of information about investments owned by investment company." } } }, "auth_ref": [ "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1005", "r1007", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1037", "r1038", "r1039", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061" ] }, "casi_ScheduleOfLongTermInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ScheduleOfLongTermInvestmentsLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsSummaryOfLongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Long Term Investments [Line Items]", "terseLabel": "Schedule Of Long Term Investments" } } }, "auth_ref": [] }, "casi_ScheduleOfLongTermInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ScheduleOfLongTermInvestmentsTable", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsSummaryOfLongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information pertaining to long term investments.", "label": "Schedule Of Long Term Investments [Table]" } } }, "auth_ref": [] }, "casi_ScheduleOfLongTermInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ScheduleOfLongTermInvestmentsTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for long term investments.", "label": "Schedule Of Long Term Investments [Table Text Block]", "terseLabel": "Schedule of components of long-term investments" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPpeDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r14", "r738" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsPurchaseOfOrdinarySharesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r233", "r240", "r241", "r745", "r746", "r748", "r954", "r955", "r958" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationCompensationExpenseDetails", "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails", "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r495", "r497", "r499", "r500", "r501", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r522", "r523", "r524", "r525", "r526", "r527", "r532" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationStockOptionOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]", "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices." } } }, "auth_ref": [ "r47" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]", "terseLabel": "Schedule of stock options outstanding", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } }, "auth_ref": [ "r47" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Schedule of stock option plans and of changes in options outstanding under the plans", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r17", "r18", "r117" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of weighted-average assumptions used in valuing the stock options", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r122" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails" ], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r39", "r40", "r41", "r42", "r43", "r44", "r114", "r115", "r116", "r195", "r196", "r197", "r277", "r452", "r453", "r454", "r456", "r459", "r464", "r466", "r659", "r890", "r891", "r892", "r893", "r1133", "r1338", "r1382", "r1384" ] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Schedule of reconciliation of gross unrecognized tax benefits", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r565", "r1148" ] }, "casi_ScheduleOfWarrantActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ScheduleOfWarrantActivityTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure related to the share based warrant activity.", "label": "Schedule Of Warrant Activity [Table Text Block]", "terseLabel": "Schedule of share purchase warrants activity" } } }, "auth_ref": [] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of expected future amortization expense", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r1094", "r1430" ] }, "casi_SecuritiesPurchaseAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "SecuritiesPurchaseAgreementsAbstract", "lang": { "en-us": { "role": { "label": "Securities Purchase Agreements [Abstract]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1227" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails", "http://www.entremed.com/role/DisclosureLeasesDetails", "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r152", "r154", "r157", "r159", "r160", "r161", "r162", "r163", "r165", "r166", "r167", "r168", "r169", "r171", "r172", "r173", "r281", "r305", "r306", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r831", "r832", "r833", "r834", "r915", "r916", "r918", "r993", "r1009", "r1031", "r1058", "r1068", "r1070", "r1071", "r1072", "r1077", "r1078", "r1079", "r1080", "r1082", "r1083", "r1084", "r1085", "r1086", "r1093", "r1114", "r1134", "r1135", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1211", "r1217", "r1546", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r303", "r305", "r1119", "r1120", "r1123" ] }, "casi_SelectedAndasToBeTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "SelectedAndasToBeTransferred", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the selected and as to be transferred.", "label": "Selected Andas To Be Transferred", "verboseLabel": "Value of transfer of selected ANDAs" } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense", "negatedLabel": "Selling and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense [Member]", "terseLabel": "Sales and marketing", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r93" ] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Shares", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r1359", "r1360", "r1450", "r1453" ] }, "casi_ServiceFeePerMonth": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ServiceFeePerMonth", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of service fee for each month for usage of office facility.", "label": "Service Fee Per Month", "terseLabel": "service charge" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationCompensationExpenseDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation.", "verboseLabel": "Share-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r10" ] }, "casi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were exercisable during the reporting period", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable", "terseLabel": "Exercisable" } } }, "auth_ref": [] }, "casi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Exercise Price", "terseLabel": "Exercisable" } } }, "auth_ref": [] }, "casi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercise In Period", "negatedTerseLabel": "Exercised" } } }, "auth_ref": [] }, "casi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of equity instruments other than options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other than Options, Exercised In Period, Weighted Average Exercise Price", "terseLabel": "Exercised" } } }, "auth_ref": [] }, "casi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedExpireTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedExpireTerms", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the expire date of stock other than option granted under share based compensation", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Expire Terms", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Expire Terms" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Issued", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r514" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Issued", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r514" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r511", "r512" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Warrants", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r511", "r512" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "verboseLabel": "Expected dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r525" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "verboseLabel": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r524" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Range of expected volatility, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r524" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Range of expected volatility, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r524" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r526" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Range of risk free interest rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r526" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Range of risk free interest rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r526" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationCompensationExpenseDetails", "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails", "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r495", "r497", "r499", "r500", "r501", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r522", "r523", "r524", "r525", "r526", "r527", "r532" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Shares that are available for grants and awards", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r1147" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "verboseLabel": "Shares available for grants", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r47" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r505" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable (in dollars per share)", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r505" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Expired (in shares)", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r510" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r509" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails", "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)", "verboseLabel": "Granted shares of common stock", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r507" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair value of share options", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r517" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r503", "r504" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending Balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r503", "r504" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price" } } }, "auth_ref": [] }, "casi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPlanModificationInPeriodWeightedAverageModificationDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPlanModificationInPeriodWeightedAverageModificationDateFairValue", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The weighted average modification-date fair value of modified options during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Plan Modification In Period, Weighted Average Modification Date Fair Value", "terseLabel": "Weighted average modification date fair value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest (in shares)", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r519" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest (in dollars per share)", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r519" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost", "terseLabel": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost", "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification." } } }, "auth_ref": [ "r531" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails", "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r499", "r500", "r501", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r523", "r524", "r525", "r526", "r527" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r508" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r510" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r509" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails", "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)", "verboseLabel": "Common stock exercise price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r507" ] }, "casi_ShareBasedCompensationExpenseToBePaidOverRemainingVestingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ShareBasedCompensationExpenseToBePaidOverRemainingVestingPeriod", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of share-based compensation expense to be paid over the remaining vesting period.", "label": "Share-based Compensation Expense To Be Paid Over The Remaining Vesting Period", "terseLabel": "Recognized through the remaining vesting period of each of the original unvested awards" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "terseLabel": "Share-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r494", "r502", "r521", "r522", "r523", "r524", "r527", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationStockOptionOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationStockOptionOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit", "verboseLabel": "Range of Exercise Prices Lower Range Limit (in dollars per share)", "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r48" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationStockOptionOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options", "verboseLabel": "Options Exercisable, Number Exercisable (in shares)", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } }, "auth_ref": [ "r120" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationStockOptionOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options", "verboseLabel": "Options Outstanding, Number Outstanding (in shares)", "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices." } } }, "auth_ref": [ "r118", "r119" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationStockOptionOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit", "verboseLabel": "Range of Exercise Prices Upper Range Limit (in dollars per share)", "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r48" ] }, "casi_ShareBasedPaymentCashReceivedFromStockOptionExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ShareBasedPaymentCashReceivedFromStockOptionExercises", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents the amount share-based payment cash received from stock option exercises.", "label": "Share Based Payment Cash Received from Stock Option Exercises", "terseLabel": "Share Based Payment Cash Received from Stock Option Exercises" } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharePrice", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails" ], "lang": { "en-us": { "role": { "label": "Share Price", "terseLabel": "Offering price per share", "verboseLabel": "Exercise price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Weighted average expected option life (in years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r523" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "verboseLabel": "Exercisable - Weighted Average Remaining Contractual Term In Years", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r47" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted Average Remaining Contractual Term In Years", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r121" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest - Weighted Average Remaining Contractual Term In Years", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r519" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationStockOptionOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price", "verboseLabel": "Options Exercisable, Weighted Average Exercise Price (in dollars per share)", "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding." } } }, "auth_ref": [ "r120" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationStockOptionOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price", "verboseLabel": "Options Outstanding, Weighted Average Exercise Price (in dollars per share)", "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices." } } }, "auth_ref": [ "r118", "r119" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationStockOptionOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term", "verboseLabel": "Options Outstanding, Weighted Average Remaining Contractual Life (in years)", "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r121" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Share issued price", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "casi_SharesIssuedPricePerShareNetOfExercisePriceOfWarrants": { "xbrltype": "perShareItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "SharesIssuedPricePerShareNetOfExercisePriceOfWarrants", "presentation": [ "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued, net of exercise price of warrants.", "label": "Shares Issued Price Per Share, Net Of Exercise Price Of Warrants", "terseLabel": "Exercise price per share", "verboseLabel": "Issuance price" } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharesOutstanding", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermBankLoansAndNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShortTermBankLoansAndNotesPayable", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Short-Term Bank Loans and Notes Payable", "terseLabel": "Bank borrowings", "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer." } } }, "auth_ref": [ "r61", "r925", "r1545" ] }, "us-gaap_ShortTermBorrowingsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShortTermBorrowingsAbstract", "lang": { "en-us": { "role": { "label": "SHORT TERM BORROWINGS" } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShortTermDebtTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureShortTermBorrowings" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Text Block]", "terseLabel": "SHORT TERM BORROWINGS", "documentation": "The entire disclosure for short-term debt." } } }, "auth_ref": [ "r111" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueAlestaTherapeuticsBvDetails", "http://www.entremed.com/role/DisclosureShareBasedCompensationStockOptionOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r149", "r195", "r196", "r197", "r233", "r236", "r264", "r265", "r267", "r269", "r277", "r278", "r347", "r413", "r415", "r416", "r417", "r420", "r421", "r441", "r442", "r444", "r445", "r447", "r449", "r452", "r453", "r456", "r459", "r466", "r702", "r890", "r891", "r892", "r893", "r900", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r930", "r950", "r974", "r1062", "r1063", "r1064", "r1065", "r1066", "r1338", "r1384", "r1386", "r1395" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsBioinventInternationalAbSummaryOfInvestmentsDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r16", "r74", "r77", "r78", "r178", "r179", "r180", "r211", "r212", "r213", "r245", "r246", "r247", "r249", "r256", "r258", "r260", "r276", "r348", "r349", "r400", "r439", "r468", "r533", "r577", "r578", "r586", "r587", "r588", "r590", "r644", "r645", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r672", "r713", "r714", "r715", "r716", "r717", "r719", "r723", "r725", "r741", "r856", "r874", "r875", "r876", "r900", "r974" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails", "http://www.entremed.com/role/DisclosureLeasesDetails", "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r152", "r154", "r157", "r159", "r160", "r161", "r162", "r163", "r165", "r166", "r167", "r168", "r169", "r171", "r172", "r173", "r281", "r305", "r306", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r831", "r832", "r833", "r834", "r915", "r916", "r918", "r993", "r1009", "r1031", "r1058", "r1068", "r1070", "r1071", "r1072", "r1077", "r1078", "r1079", "r1080", "r1082", "r1083", "r1084", "r1085", "r1086", "r1093", "r1114", "r1134", "r1135", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1211", "r1217", "r1546", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementLineItems", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r245", "r246", "r247", "r276", "r441", "r442", "r444", "r447", "r725", "r788", "r885", "r901", "r912", "r921", "r922", "r923", "r924", "r926", "r927", "r930", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r943", "r944", "r945", "r946", "r947", "r952", "r953", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r974", "r1108", "r1110", "r1218", "r1584" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "verboseLabel": "Comprehensive loss:" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementTable", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r245", "r246", "r247", "r276", "r308", "r441", "r442", "r444", "r447", "r725", "r788", "r885", "r901", "r912", "r921", "r922", "r923", "r924", "r926", "r927", "r930", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r943", "r944", "r945", "r946", "r947", "r952", "r953", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r974", "r1108", "r1110", "r1218", "r1584" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r1247", "r1258", "r1268", "r1301" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [ "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsPurchaseOfOrdinarySharesDetails", "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r16", "r73", "r74", "r116", "r890", "r974", "r1063" ] }, "casi_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) and warrants exercised during the current period.", "label": "Stock Issued During Period, Shares, Stock Options And Warrants Exercised", "terseLabel": "Issuance of ordinary shares for options and warrants exercised (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationOptionsOutstandingDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Issuance of ordinary shares for options exercised (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r16", "r73", "r74", "r116", "r508" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails", "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of ordinary share pursuant to a PIPE Transaction", "verboseLabel": "Proceeds from sale of ordinary shares", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r16", "r73", "r74", "r116", "r900", "r974", "r1063", "r1224" ] }, "casi_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options and warrants.", "label": "Stock Issued During Period, Value, Stock Options And Warrants Exercised", "terseLabel": "Issuance of ordinary shares for options and warrants exercised" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of ordinary shares for options exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r16", "r74", "r77", "r78", "r116" ] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails" ], "lang": { "en-us": { "role": { "label": "Stock Repurchase Program, Authorized Amount", "verboseLabel": "Stock repurchased authorized amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1455" ] }, "srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails" ], "lang": { "en-us": { "role": { "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "verboseLabel": "Stock repurchase authorized (in shares)", "documentation": "Number of shares authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1455" ] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased and Retired During Period, Shares", "negatedLabel": "Repurchase of ordinary shares (in shares)", "verboseLabel": "Repurchase and retirement stock (in shares)", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": [ "r16", "r73", "r74", "r116" ] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased and Retired During Period, Value", "negatedLabel": "Repurchase of ordinary shares", "verboseLabel": "Repurchase and retirement of common stock", "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)." } } }, "auth_ref": [ "r16", "r73", "r74", "r116" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Shares", "terseLabel": "Repurchase of common stock (in shares)", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r16", "r73", "r74", "r116", "r893", "r974", "r1065" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Value", "terseLabel": "Repurchase of common stock", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r16", "r73", "r74", "r116", "r900", "r974", "r1065", "r1224" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets", "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total shareholders' (deficit) equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r74", "r77", "r78", "r103", "r932", "r948", "r975", "r976", "r1199", "r1225", "r1382", "r1386", "r1387", "r1421", "r1526", "r1585" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders' (deficit) equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "SHAREHOLDERS' (DEFICIT) EQUITY" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "SHAREHOLDERS' (DEFICIT) EQUITY", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r113", "r451", "r453", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r465", "r468", "r659", "r671", "r977", "r979", "r1067" ] }, "casi_SublicensingRevenueFromRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "SublicensingRevenueFromRelatedParty", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPrecisionAutoimmuneTherapeuticsCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Sublicensing revenue from a related party.", "label": "Sublicensing Revenue From Related Party", "terseLabel": "Sublicensing revenue from a related party" } } }, "auth_ref": [] }, "casi_SubscriptionPeriodForWarrants": { "xbrltype": "durationItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "SubscriptionPeriodForWarrants", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Period for subscription of warrants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Subscription Period For Warrants", "terseLabel": "Subscription period for warrants (in years)" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.entremed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Events", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r720", "r752" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventMember", "presentation": [ "http://www.entremed.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails", "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails", "http://www.entremed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Events", "verboseLabel": "Subsequent event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r720", "r752" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTable", "presentation": [ "http://www.entremed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r720", "r752" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.entremed.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails", "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails", "http://www.entremed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r720", "r752" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.entremed.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails", "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsConvertibleNoteFinancingDetails", "http://www.entremed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r720", "r752" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r751", "r753" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShareDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsPurchaseOfOrdinarySharesDetails", "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SummaryOfValuationAllowanceTextBlock", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Summary of Valuation Allowance [Table Text Block]", "terseLabel": "Schedule of valuation allowance", "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance." } } }, "auth_ref": [ "r1494" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r1294" ] }, "us-gaap_TangibleAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TangibleAssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosurePropertyPlantAndEquipmentNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Tangible Asset Impairment Charges", "verboseLabel": "Impairment of property, plant and equipment", "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value." } } }, "auth_ref": [ "r59", "r107" ] }, "casi_TargetCompaniesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "TargetCompaniesMember", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to target companies being BI-1206 (in China), CID-103(in Asia excluding Japan) and Thiotepa (in China excluding Hong Kong, Macau and Taiwan).", "label": "Target Companies [Member]", "terseLabel": "Target companies" } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Amount", "terseLabel": "Operating loss carryforwards, tax", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r575" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r575" ] }, "casi_TaxCreditCarryforwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "TaxCreditCarryforwardExpirationPeriod", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "Period in which tax credit carryforwards expire in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.", "label": "Tax Credit Carryforward, Expiration Period", "terseLabel": "Expiration period for unused tax carryforwards" } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r575" ] }, "us-gaap_TaxJurisdictionOfDomicileExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TaxJurisdictionOfDomicileExtensibleEnumeration", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Tax Jurisdiction of Domicile [Extensible Enumeration]", "terseLabel": "Tax Jurisdiction of Domicile [Extensible Enumeration]", "documentation": "Indicates tax jurisdiction of domicile." } } }, "auth_ref": [ "r553", "r1149" ] }, "casi_TermOfAgreement": { "xbrltype": "durationItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "TermOfAgreement", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsChinaResourcesPharmaceuticalCommercialGroupInternationalTradingCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsGuangzhouGloriaBiosciencesCoLtdDetails" ], "lang": { "en-us": { "role": { "documentation": "Term of Agreement.", "label": "Term of Agreement", "terseLabel": "Term of agreement (in years)" } } }, "auth_ref": [] }, "casi_TermOfAnniversaryAfterMaturityOfLoan": { "xbrltype": "durationItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "TermOfAnniversaryAfterMaturityOfLoan", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "documentation": "Term of anniversary after the maturity of loan.", "label": "Term of Anniversary After the Maturity of Loan", "terseLabel": "Loan, conversion term (in years)" } } }, "auth_ref": [] }, "casi_ThresholdConsecutiveTradingsDaysForComputingAverageClosingPrice": { "xbrltype": "integerItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "ThresholdConsecutiveTradingsDaysForComputingAverageClosingPrice", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which average closing price of ordinary share is computed.", "label": "Threshold Consecutive Tradings Days For Computing Average Closing Price", "terseLabel": "Threshold consecutive tradings days for computing average closing price" } } }, "auth_ref": [] }, "casi_TimeBasedStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "TimeBasedStockOptionsMember", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to time based stock options.", "label": "Time Based Stock Options [Member]", "terseLabel": "Time Based Stock Options" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.entremed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "documentation": "Information by title and position of individual or group within organization." } } }, "auth_ref": [ "r1408", "r1533" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.entremed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Relationship to Entity [Domain]", "documentation": "Title and position of individual or group within organization." } } }, "auth_ref": [] }, "casi_TotalMilestoneConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "TotalMilestoneConsideration", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "The total consideration paid over the term of the agreement.", "label": "Total Milestone Consideration", "terseLabel": "Total consideration paid over term of agreement" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r1286" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r1293" ] }, "casi_TotalUnrecognizedShareBasedCompensationCostExpectedToBeRecognizedOverWeightedAveragePeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "TotalUnrecognizedShareBasedCompensationCostExpectedToBeRecognizedOverWeightedAveragePeriod", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Total unrecognized compensation cost expected to be recognized over a weighted-average period.", "label": "Total Unrecognized Share Based Compensation Cost Expected To Be Recognized Over Weighted Average Period", "terseLabel": "Total unrecognized compensation expense related to non-vested share options" } } }, "auth_ref": [] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Prepaid expenses and other", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r1410", "r1411", "r1412" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r1314" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r1316" ] }, "us-gaap_TradingSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TradingSecuritiesDebt", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsSummaryOfLongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Trading", "terseLabel": "Carrying amount", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": [ "r193", "r676", "r695", "r696", "r697", "r698", "r1092", "r1097", "r1196", "r1413", "r1515", "r1516", "r1517" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://www.entremed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsSummaryOfLongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r438", "r464", "r659", "r670", "r694", "r701", "r704", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r838", "r857", "r1186", "r1187", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1200", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1414", "r1415", "r1416", "r1417", "r1512", "r1515", "r1516", "r1517", "r1518", "r1519", "r1521", "r1522" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r1317" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r1318" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r1318" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1316" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r1316" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r1319" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r1317" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.entremed.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r45" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.entremed.com/role/DisclosureShareholdersDeficitEquityDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury stock, Shares Held (in shares)", "verboseLabel": "Common stock in treasury (in shares)", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r45" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://www.entremed.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.entremed.com/role/DisclosureCondensedFinancialInformationOfRegistrantCondensedBalanceSheetsDetails", "http://www.entremed.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Value", "negatedLabel": "Treasury shares, at cost: 411,996 shares and 411,952 shares held at December 31, 2025 and 2024", "negatedTerseLabel": "Treasury shares", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r45", "r46", "r74", "r77" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsChinaResourcesPharmaceuticalCommercialGroupInternationalTradingCoLtdDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsCleaveTherapeuticsIncDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLiquidityAndCapitalResourcesDetails", "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInPrecisionAutoimmuneTherapeuticsCoLtdPatDetails" ], "lang": { "en-us": { "role": { "label": "Type of Arrangement and Non-arrangement Transactions [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r646" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "US", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails", "http://www.entremed.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails", "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "UNITED STATES", "verboseLabel": "United States" } } }, "auth_ref": [] }, "casi_UnderpaymentOfTaxesStatueOfLimitationExtendedTerm": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "UnderpaymentOfTaxesStatueOfLimitationExtendedTerm", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of underpayment of taxes leads to extension of statue of limitation.", "label": "Underpayment of Taxes, Statue of Limitation Extended term", "terseLabel": "Underpayment of taxes, statue of limitation extended term" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r1313" ] }, "casi_UnrealizedGains": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "UnrealizedGains", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease), resulting in a gain, that was included in earnings for the period.", "label": "Unrealized Gains", "terseLabel": "Unrealized gains" } } }, "auth_ref": [] }, "casi_UnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "UnrealizedLoss", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease), resulting in a loss, that was included in earnings for the period.", "label": "Unrealized Loss", "terseLabel": "Unrealized losses" } } }, "auth_ref": [] }, "casi_UnrecognizedShareBasedCompensationCostExpectedToRecognizeOverWeightedAveragePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "UnrecognizedShareBasedCompensationCostExpectedToRecognizeOverWeightedAveragePeriod", "presentation": [ "http://www.entremed.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Unrecognized compensation cost is expected to be recognized over a weighted-average period.", "label": "Unrecognized Share Based Compensation Cost Expected To Recognize Over Weighted Average Period", "terseLabel": "Unrecognized compensation cost is expected to be recognized over a weighted-average period (in years)" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails", "http://www.entremed.com/role/DisclosureIncomeTaxesGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "verboseLabel": "Unrecognized tax benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r548", "r565", "r1148" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails", "http://www.entremed.com/role/DisclosureIncomeTaxesGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedLabel": "Reductions for tax positions of prior periods", "terseLabel": "Net reduction of unrecognized tax benefits", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r566", "r1148" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Income tax, interest or penalties", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r563", "r1148" ] }, "casi_UpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "UpfrontPayment", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBioinventInternationalAbDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsBlackBeltTherapeuticsLimitedDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsCleaveTherapeuticsIncDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPharmathenGlobalBvDetails", "http://www.entremed.com/role/DisclosureDescriptionOfBusinessLicenseAndDistributionAgreementsPrecisionAutoimmuneTherapeuticsCoLtdDetails", "http://www.entremed.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of upfront payment.", "label": "Upfront Payment", "terseLabel": "Upfront payment" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UseOfEstimates", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r142", "r143", "r279", "r282", "r283", "r284", "r831", "r833", "r1115" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.entremed.com/role/DisclosureIncomeTaxesValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Decrease from attribute expiration", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r569" ] }, "us-gaap_ValueAddedTaxReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ValueAddedTaxReceivable", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPrepaidExpensesAndOtherDetails" ], "lang": { "en-us": { "role": { "label": "Value Added Tax Receivable", "terseLabel": "Deductible Value Added Tax (\"VAT\")", "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities." } } }, "auth_ref": [ "r1361" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": [ "http://www.entremed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Variable Lease, Cost", "verboseLabel": "Variable lease costs", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r732", "r1198" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r1282" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantMember", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsBioinventInternationalAbSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrants", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r1215", "r1216", "r1219", "r1220", "r1221", "r1222" ] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Warrants , Measurement Input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r1515", "r1516", "r1517" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.entremed.com/role/DisclosureInvestmentInEquitySecuritiesAtFairValueAndLongTermInvestmentsInvestmentInEquitySecuritiesAtFairValueBioinventInternationalAbOrdinarySharesAndWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrants expected life (in years)", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1515", "r1516", "r1517" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareComputationDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Denominator for basic and diluted net loss per share calculation", "verboseLabel": "Weighted average number of ordinary stock outstanding (diluted)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r263", "r269" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareComputationDetails", "http://www.entremed.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of ordinary shares outstanding (basic)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r262", "r269" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.entremed.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareComputationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Denominator:" } } }, "auth_ref": [] }, "casi_WuxiLpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.entremed.com/20251231", "localname": "WuxiLpMember", "presentation": [ "http://www.entremed.com/role/DisclosureRedeemableNoncontrollingInterestAndLongTermBorrowingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to WUXI LP.", "label": "WUXI LP [Member]", "terseLabel": "WUXI LP" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r1280" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-24" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-23" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "10", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Footnote": "4", "Publisher": "SEC" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "3", "Publisher": "SEC" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column B", "Publisher": "SEC" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column C", "Publisher": "SEC" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-4A" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-5A" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479366/326-20-35-8A" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-5" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-17" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-21" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3C" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.M.2.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483530/326-20-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479175/326-30-30-1B" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "13A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-13A" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-7A" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3C" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3D" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(24)(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2AG", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AG" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-9" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-5" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-21" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "805", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r943": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r944": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r945": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r946": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r947": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r948": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r949": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r950": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r951": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r952": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r953": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r954": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r955": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r956": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r957": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r958": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r959": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r960": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r961": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r962": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r963": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r964": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r965": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r966": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r967": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r968": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r969": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r970": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r971": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r972": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r973": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r974": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r975": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r976": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r977": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r978": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r979": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r980": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r981": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r982": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/946-320/tableOfContent" }, "r983": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r984": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r985": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r986": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r987": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r988": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r989": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r990": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r991": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r992": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r993": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r994": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r995": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r996": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r997": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r998": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r999": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1000": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1001": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1002": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1003": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1004": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r1005": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r1006": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r1007": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r1008": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1009": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1010": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1011": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1012": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1013": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1014": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1015": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1016": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1017": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1018": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1019": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1020": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1021": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1022": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1023": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1024": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1025": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1026": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1027": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1028": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1029": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1030": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1031": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1032": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1033": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1034": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1035": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r1036": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r1037": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1038": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1039": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1040": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1041": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1042": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1043": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1044": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1045": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1046": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1047": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1048": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1049": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1050": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1051": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column C)(Footnote 6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1052": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1053": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1054": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1055": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1056": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1057": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1058": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1059": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1060": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1061": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1062": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r1063": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1064": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1065": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1066": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1067": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r1068": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2" }, "r1069": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1070": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1071": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1072": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1073": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4" }, "r1074": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2" }, "r1075": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r1076": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r1077": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1078": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1079": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1080": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1081": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1082": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1083": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1084": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1085": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1086": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1087": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r1088": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r1089": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r1090": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r1091": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1092": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10" }, "r1093": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1094": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r1095": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1096": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1097": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1098": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1099": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1100": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1101": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r1102": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r1103": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r1104": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12" }, "r1105": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11" }, "r1106": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14" }, "r1107": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18" }, "r1108": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21" }, "r1109": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24" }, "r1110": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4" }, "r1111": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1112": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1113": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r1114": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18" }, "r1115": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6" }, "r1116": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1117": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r1118": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1119": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1120": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1121": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r1122": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r1123": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1124": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1125": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r1126": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r1127": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1128": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r1129": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r1130": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r1131": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r1132": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "64", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64" }, "r1133": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1134": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1135": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1136": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1137": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1138": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1139": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r1140": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r1141": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r1142": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18" }, "r1143": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1144": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1145": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r1146": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1147": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1148": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r1149": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r1150": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8" }, "r1151": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41" }, "r1152": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "43", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43" }, "r1153": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47" }, "r1154": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1155": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1156": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1157": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1158": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1159": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r1160": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r1161": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r1162": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r1163": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29" }, "r1164": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29" }, "r1165": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1166": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1167": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1168": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1169": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1170": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1171": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1172": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1173": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1174": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1175": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1176": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1177": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1178": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1179": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1180": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1181": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r1182": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r1183": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1184": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r1185": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "184", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184" }, "r1186": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1187": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r1188": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r1189": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r1190": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1191": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1192": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1193": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1194": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1195": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1196": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12" }, "r1197": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r1198": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r1199": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r1200": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r1201": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r1202": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r1203": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r1204": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r1205": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r1206": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r1207": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r1208": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r1209": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1210": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r1211": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1212": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1213": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11" }, "r1214": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14" }, "r1215": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1216": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1217": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r1218": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1219": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1220": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1221": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1222": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1223": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r1224": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r1225": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r1226": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1227": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1228": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1229": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r1230": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r1231": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r1232": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r1233": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r1234": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1235": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1236": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1237": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r1238": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r1239": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r1240": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1241": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1242": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r1243": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r1244": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r1245": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1246": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1247": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1248": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1249": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1250": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r1251": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r1252": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r1253": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r1254": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r1255": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r1256": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1257": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1258": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1259": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1260": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1261": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1262": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1263": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1264": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1265": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1266": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1267": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1268": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1269": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1270": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1271": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1272": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1273": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1274": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1275": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1276": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r1277": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1278": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r1279": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r1280": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r1281": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r1282": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r1283": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r1284": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r1285": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r1286": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1287": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1288": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1289": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1290": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1291": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1292": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1293": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1294": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1295": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1296": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r1297": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1298": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1299": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1300": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1301": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1302": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1303": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1304": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1305": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1306": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1307": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1308": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1309": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1310": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1311": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1312": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1313": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1314": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1315": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1316": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1317": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1318": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1319": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1320": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1321": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r1322": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r1323": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1324": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1325": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1326": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r1327": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r1328": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r1329": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1330": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1331": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r1332": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1333": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1334": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1335": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1336": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1337": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r1338": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1339": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1340": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1341": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1342": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-11" }, "r1343": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1344": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org/705/tableOfContent" }, "r1345": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r1346": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r1347": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r1348": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r1349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1350": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r1352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r1353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r1354": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r1355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r1356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "6", "Subsection": "04", "Paragraph": "12", "Subparagraph": "(b)(1)", "Publisher": "SEC" }, "r1357": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1358": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1359": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1360": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1361": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1362": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1363": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1364": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1365": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1366": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1367": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1368": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1369": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1370": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r1371": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12" }, "r1372": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1373": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1374": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1375": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1376": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1377": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1378": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1379": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1380": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r1381": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1382": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r1383": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r1384": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1385": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1386": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1387": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1388": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1389": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1390": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1391": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1392": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1393": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1394": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1395": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1396": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1397": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1398": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1399": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1400": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1401": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1402": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1403": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1404": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1405": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1406": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1407": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1408": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1409": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1410": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1411": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1412": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r1413": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r1414": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1415": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1416": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1417": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1418": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4" }, "r1419": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r1420": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1421": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1422": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1423": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1424": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1425": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1426": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1427": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1428": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1429": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1430": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1431": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1432": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1433": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1434": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r1435": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1436": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1437": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1438": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1439": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1440": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1441": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1442": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1443": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1444": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1445": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r1448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3" }, "r1450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r1451": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3" }, "r1452": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(24)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r1453": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r1454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r1455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "710", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/710/tableOfContent" }, "r1457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/712/tableOfContent" }, "r1458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r1459": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1460": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r1461": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r1462": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1463": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1464": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1465": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1466": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1479": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1483": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2" }, "r1489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r1490": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1501": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1502": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1503": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r1504": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r1505": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r1506": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A" }, "r1507": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1508": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1509": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1510": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r1511": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r1521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r1522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r1523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r1524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-13" }, "r1525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3" }, "r1532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r1533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r1545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } }